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ABSTRACT 
 
Mrudula Borse Glassberg: Comparative effectiveness and safety of anticoagulants in the 
prevention of venous thromboembolism in elective hip and knee replacement surgery patients 
(Under the direction of Stacie Dusetzina) 
 
 
One of the serious complications after elective hip or knee replacement surgery 
is venous thromboembolism and use of anticoagulants is recommended for prophylaxis. 
Rivaroxaban is a newer oral anticoagulant and offers multiple benefits over standard 
anticoagulants. However, the safety and effectiveness of rivaroxaban beyond clinical 
trials is unknown. This study examined the comparative effectiveness and safety of 
rivaroxaban versus warfarin in elective hip and knee replacement patients. 
A retrospective cohort of commercial and Medicare patients newly initiating 
rivaroxaban or warfarin after hip or knee replacement surgery between January 1, 2011 
and December 31, 2015 was identified. Patients who were new users of treatment, 
continuously enrolled for 6 months during the baseline period and three months after 
the surgery, and older than 18 years were included. Logistic regression with IPTW was 
used to examine the association between the choice of anticoagulant and VTE, 
bleeding and post-operative joint infection risk.  
Of the 117,393 commercially insured patients undergoing elective total hip 
replacement, 12,876 and 10,892 were new users of warfarin and rivaroxaban 
respectively. Of the 67,207 Medicare patients undergoing total hip replacement, 7,416 
and 4,739 were new users of warfarin and rivaroxaban respectively. Of the 212,808 
commercially insured knee replacement patients, 24,856 initiated warfarin and 21,398 
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initiated rivaroxaban. Of the 132,073 Medicare knee replacement patients, 15,483 and 
8,997 were new users of warfarin and rivaroxaban respectively. Among total hip 
replacement patients, warfarin users had significantly higher odds of deep vein 
thrombosis (OR 2.63,95%CI 1.97-3.50 in commercial cohort and OR 1.78,95%CI 1.38-
2.29 in Medicare cohort) and pulmonary embolism (OR 2.60,95%CI 2.04-3.31 in 
commercial cohort and OR 2.09,95%CI 1.66-2.65 in Medicare cohort). The odds of 
deep vein thrombosis (OR 2.06,95%CI 1.76-2.42 in commercial cohort and OR 
2.21,95%CI 1.84-2.65 in Medicare cohort) and pulmonary embolism (OR 2.03,95%CI 
1.78-2.33 in commercial cohort and OR 2.16,95%CI 1.84-2.55 in Medicare cohort) were 
also higher among warfarin users in the total knee replacement cohorts. There were no 
statistically significant differences in the bleeding risk among rivaroxaban and warfarin 
users. The odds of postoperative joint infection (OR 1.57,95%CI 1.16 -2.13 in 
commercial cohort and OR 1.79,95%CI 1.14-2.81 in Medicare cohort) were significantly 
higher in warfarin users compared to rivaroxaban users.  
The results from this dissertation suggest that treatment with rivaroxaban may 
help reduce the risk of incident VTE events without any significant increase in the risk of 
bleeding or post-operative joint infection compared to warfarin in patients with hip or 
knee replacement. 
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Chapter 1 : INTRODUCTION 
 
  1.1 Overview 
Deep vein thrombosis and pulmonary embolism, collectively known as venous 
thromboembolism (VTE), is one of the most serious complications after major 
orthopedic surgery, including total knee replacement and total hip replacement 
surgery.1-3 It is often associated with significant morbidity and mortality.4  Standard 
pharmacological prophylaxis includes use of unfractionated heparin, low molecular 
weight heparin (LMWH), fondaparinux, and warfarin.5  Although these standard 
therapies are effective in preventing VTE, they have several limitations. LMWHs and 
fondaparinux require injection or infusion, which may cause discomfort among patients 
and can therefore lead to non-compliance.6,7  Warfarin has a narrow therapeutic window 
and requires diet and international normalized ratio (INR) monitoring.7   
Due to the limitations of standard anticoagulants, recently approved oral 
anticoagulants like dabigatran, apixaban, and rivaroxaban (known as “novel oral 
anticoagulants” or “target-specific oral anticoagulants”) are emerging as potential 
alternatives in VTE prevention. Randomized clinical trials have demonstrated that novel 
oral anticoagulants are superior or non-inferior compared to standard therapy for 
prophylaxis of VTE after hip and knee replacement surgeries. 8  Moreover, novel oral 
anticoagulants provide the additional benefit of oral administration and do not require 
INR monitoring or dietary restrictions.6 These benefits may lead to better treatment 
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compliance and VTE prevention than the standard anticoagulation regimen in a routine 
practice setting. However, uncertainty remains about their relative safety, because, 
unlike warfarin, most of these newer anticoagulants lack a direct reversal agent in the 
event of bleeding complications. 6 Regardless, the utilization and clinical effectiveness 
of novel oral anticoagulants in the prevention of VTE compared with standard therapy 
such as warfarin remains unclear in real-world clinical practice. 
           Examining the comparative effectiveness of anticoagulants also necessitates 
understanding the factors associated with the choice of a particular treatment, 
especially new pharmaceuticals. If certain characteristics are significantly associated 
with the use of one therapy versus another, the apparent comparative effectiveness 
could be affected, particularly if those characteristics also affect outcomes. Optimal 
treatment selection may also differ in specific patient populations and understanding the 
risk of clinical outcomes among subgroups can help patients and providers in deciding 
between anticoagulants. Hence, it is also important to understand the factors associated 
with the choice of anticoagulant for these patients.     
1.2 Significance 
           Each year, there are more than 719,000 total knee replacements and 332,000 
total hip replacements performed in the United States.9  Among these commonly 
performed procedures, the incidence rate of VTE is 42-57% in hip arthroplasty and 41-
85% in knee arthroplasty. 10 VTE is the third most prevalent cardiovascular condition 
and is associated with significant morbidity, mortality, and use of healthcare resources.4 
In fact, VTE is the leading cause of all preventable hospital deaths.4,11,12 The cumulative 
risk of recurrent VTE among those who do not receive treatment after a primary episode 
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of VTE increases from 11% in one year up to 40% within 10 years.13 The annual direct 
medical cost of patients who have VTE is $32,918, while the direct medical cost of 
those who have recurrent VTE events is $82,110, costing the U.S. healthcare system 
approximately $15.5 billion each year.14,15 Optimizing anticoagulation after a hip or knee 
replacement  surgery is a critical public health need.4 
Although various clinical guidelines recommend prophylactic anticoagulation 
therapy after hip or knee replacement surgery, real-world treatment patterns in these 
patients have yet to be examined.16,17 Understanding the factors associated with the 
use of anticoagulants in these patients may help future patient-centered research by 
examining areas where treatment-effect heterogeneity may exist. Comparative 
effectiveness research is thought to be affected by changing patterns of use in newly-
launched therapies.18,19 Furthermore, the effectiveness and safety of novel oral 
anticoagulants compared with standard prophylaxis after hip and knee replacement 
surgeries has not been studied extensively outside of randomized-clinical trials (RCTs) 
or meta-analyses of these RCTs. Moreover, the RCTs evaluating efficacy of novel oral 
anticoagulants among patients undergoing hip and knee replacement surgery are based 
on average 10-14 days and up to 35 days of anticoagulation, respectively.20-31 Literature 
suggests that the cumulative risk of venous thromboembolism lasts for up to three 
months after hip surgery and for one month after total knee replacement.32 There is no 
clear evidence of how newer oral anticoagulants perform compared to standard 
anticoagulants for prolonged VTE prophylaxis in actual practice.   
Additionally, patients enrolled in RCTs may not be true representatives of the 
actual population and may not represent variation in the length of therapy, follow up 
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time, or physician practice. Given the variation in administration and burden associated 
with treatment regimens, conducting an observational study to compare the 
effectiveness of available anticoagulants is a novel element.33 As of now, there are no 
observational studies that have used real world data to compare the effectiveness of 
novel oral anticoagulants in the prevention of VTE after hip or knee replacement 
surgery.  Recent use of electronic medical records and large healthcare databases has 
gained importance to assessing comparative effectiveness.34 This will be the first study 
that will use large insurance claims data to assess the real world effectiveness of these 
agents in hip and knee replacement surgery patients.  
We will analyze data from Truven's MarketScan Commercial Claims and 
Encounters and Medicare Supplemental and Coordination of Benefits for the years 
2010-2016 for this study. The MarketScan database contains claims submitted from 
health plans which have contracts with large private employers or public organizations 
in the United States. This longitudinal database covers all inpatient, outpatient, and 
prescription claims for individual patients for as long as they remain enrolled in the 
health plan. 
The goal of this study is to investigate the factors associated with new use of 
anticoagulants after hip and knee replacement surgeries, and to study the comparative 
effectiveness and safety of novel oral anticoagulants with standard anticoagulants in 
these patients. Because of the increasing use of newer anticoagulants, understanding 
their comparative effectiveness and safety is of critical importance. The contribution of 
the proposed research is expected to help inform patients, clinicians, researchers, and 
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third-party payers of the real-world utilization and comparative effectiveness in order to 
help improve clinical practice.  
1.3 Specific Aims 
Aim 1: To examine trends and predictors of anticoagulant use following elective total 
knee replacement or elective total hip replacement surgery. 
Aim 1a: To analyze market trends in the utilization of anticoagulants in patients 
undergoing an elective total hip or knee replacement surgery.  
We will analyze the change in uptake of various anticoagulants for VTE 
prophylaxis in elective hip and knee replacement surgery patients after the introduction 
of newer oral anticoagulants. This will help us understand the change in treatment 
patterns in clinical practice over time. 
Aim 1b: To identify factors influencing the choice of anticoagulation therapy in patients 
undergoing an elective total hip or knee replacement surgery. 
We will also design a retrospective cohort study to evaluate the influence of 
various population characteristics on the choice of anticoagulation therapy in patients 
undergoing an elective total hip or knee replacement surgery. We will use the 
Andersen’s Behavioral Model for health service use to guide variable selection for the 
analysis.35 Andersen’s Model is a multi-level model that incorporates both individual and 
contextual determinants of health care use. In this model, predisposing factors like 
patient’s age, sex, timing of surgery and geographic location influence patients’ ability 
(measured through enabling factors like health insurance type and prescription drug 
benefit generosity) to obtain health care. These factors, when added to the need for 
treatment (measured through need factors like past clinical events, concomitant 
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therapies and comorbidities), predict the use of health care services. In order to 
understand the impact of various predictors on the type of anticoagulation therapy, 
logistic regression models will be used. 
 
Aim 2: To compare the real world effectiveness of novel oral anticoagulant rivaroxaban 
with standard oral anticoagulant warfarin in venous thromboembolism prevention 
among patients with elective total hip and knee replacement surgery.  
 In this specific aim, a cohort study will be designed to compare the effectiveness 
of rivaroxaban with standard therapy (warfarin) in the prevention of venous 
thromboembolism in elective total hip and knee replacement surgery patients. We 
chose to only include rivaroxaban as the novel oral anticoagulant comparator because it 
was the first approved novel oral anticoagulant in the United States for prevention and 
treatment of VTE after a hip or knee replacement and shares almost forty percent of the 
market share of oral anticoagulants. Furthermore, apixaban and dabigatran had too 
small sample sizes to sufficiently power their individual comparisons to warfarin. 
Multiple logistic regression will be used to estimate the odds ratios controlling for 
potential confounders identified in specific aim 1. 
 
Aim 3:  To compare the safety of novel oral anticoagulant rivaroxaban with standard 
oral anticoagulant warfarin among patients with elective total hip or knee replacement 
surgery.  
 In this specific aim, we will examine the association between the use of 
rivaroxaban and warfarin and the risk of adverse events such as major bleeding, 
7 
 
intracranial hemorrhage, gastrointestinal bleeding and perioperative wound infection in 
patients undergoing elective total hip or knee replacement surgery.  
 
Research implications:  
The results of our aim 1 can improve our understanding of the utilization patterns 
and choice of anticoagulation treatment in patients undergoing elective total hip or knee 
replacement surgery. This can help identify factors and target patient subgroups for 
anticoagulation treatment initiation to maximize treatment benefit from these agents. 
Results from aims 2 and 3 can add unique information to the literature by providing 
information on whether the novel oral anticoagulants are more effective in the real world 
in improving VTE outcomes and preventing major bleed events among patients 
undergoing elective hip and knee replacement surgery. These findings will guide 
therapeutic decision-making to improve the quality of care provided to patients having 
elective knee and hip transplants. 
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Chapter 2 : BACKGROUND AND LITERATURE REVIEW 
 
In section 2.1, we provide an overview of elective total hip or knee replacement 
surgery. Section 2.2 provides a review of the literature on the relationship between hip 
and knee replacement surgery and venous thromboembolism (VTE). In section 2.3, we 
present a review of the current treatment options for VTE prophylaxis after hip and knee 
replacement surgeries. In section 2.4, we provide a review of the current evidence 
regarding effectiveness and safety of VTE treatment in arthroplasty patients. Section 2.5 
identifies the gaps in current literature and provides a rationale for the proposed study. 
In section 2.6, we describe the significance of this study and the potential implications of 
our findings. Finally, in section 2.7, we propose a theoretical framework for this study. 
2.1 Elective total hip and knee replacement surgery overview 
 Elective major orthopedic surgeries are now commonly performed in the United 
States, with approximately one million elderly operated every year.36 Elective major 
orthopedic surgeries mainly encompass hip and knee arthroplasties, more commonly 
referred to as hip and knee replacements. Hip and knee replacements are surgical 
procedures in which the hip and the knee joints, respectively, are replaced by a 
prosthetic implant. They are generally performed to alleviate arthritic pain and 
inflammation. Depending on the prognosis, they can be performed as a total 
replacement or a partial replacement. These procedures are among the most 
successful and satisfactory interventions in relieving pain, restoring joint function, and 
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improving quality of life post-surgery in these patients.37-43 With the aging of the baby 
boomer population, and higher numbers of younger patients opting for joint 
replacements, the number of hip and knee replacements are predicted to increase, and 
by 2030, there are expected to be more than 4 million replacement surgeries performed 
annually in the United States.44 As the number of total joint arthroplasties performed 
continues to grow, a commensurate increase in the number of complications associated 
with these surgeries, including venous thromboembolism (VTE) events, can be 
anticipated. As such, it important to further our understanding of the effectiveness of 
prevention strategies, especially in populations excluded from the clinical trials.  
2.2 Risk of venous thromboembolism in elective hip and knee replacement 
surgery  
 Venous thromboembolism is one of the serious complications after hip and knee 
arthroplasties, and is associated with significant morbidity and mortality.45  Without any 
prophylactic measures, the overall risk of VTE after joint replacement surgery ranges 
from 33% to 46%.45-47 Venous thromboembolism is a combination of deep vein 
thrombosis and pulmonary embolism. Deep vein thrombosis is the formation of a blood 
clot (thrombus) within a deep vein, predominantly in the legs or pelvis, causing total or 
partial blockage of blood flow. Pulmonary embolism is caused by the detachment 
(embolization) of the blood clot which then travels through the bloodstream to the lungs, 
resulting in blockage of the pulmonary arteries. Based on the level of blockage, 
pulmonary embolism is a potentially life-threatening complication.48   
 The pathophysiology of VTE and the associated risk factors were first explained 
by pathologist Rudolph Virchow in 1856.48,49 Three main pathophysiological factors, 
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commonly referred to as the Virchow’s triad, are thought to contribute to thrombosis. 
These factors are: 1) venous stasis, 2) endothelial injury and 3) hypercoagulability.50 All 
of these factors are closely linked to orthopedic surgeries, particularly major ones, like 
hip and knee arthroplasties, thereby increasing the risk for occurrence of venous 
thromboembolism post-surgery.51,52 The positioning of the limb during surgery, localized 
post-operative edema, and limited ambulation, both during and immediately after 
surgery, all play significant roles in venous stasis and the consequent reduction of blood 
flow.52,53 Surgical lesions also increase the release of thromboplastins from damaged 
endothelial lining and bone, thereby activating the clotting cascade.52 Because of all of 
these factors, the risk of VTE after hip or knee replacement surgery is particularly 
high.54  
2.3 Prophylactic measures for postoperative venous thromboembolism  
 The risk of VTE after joint replacement can be reduced by early mobilization and 
a combination of one or more of the following preventive strategies: 1) mechanical 
agents, 2) injectable agents, 3) older oral anticoagulants, and 4) newer or novel oral 
anticoagulants.45 Mechanical prevention involves the use of mechanical compression 
devices such as graduated compression stockings, intermittent pneumatic compression 
devices, and plantar venous pumps.55 They reduce venous congestion and stasis by 
squeezing the lower extremities.56,57 Mechanical devices can help prevent VTE in some 
patients and are appealing to surgeons as they do not cause hemorrhagic side effects, 
like pharmacological agents can. However, they are expensive, have low rates of 
compliance, and are impractical when the patient starts to mobilize.58  They are also 
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contraindicated in conditions such as exposed fracture, cardiac insufficiency, infection, 
and ulceration of the lower limbs.59 
Several pharmacological agents are available to surgeons for VTE prophylaxis 
after joint replacement surgeries. While mechanical devices prevent clots from travelling 
through the blood stream and reaching the lungs, anticoagulants are used to prevent 
clot formation. Pharmacological agents prevent VTE by targeting hypercoagulability, 
activating anti-coagulation factors, and preventing platelet aggregation (Figure 2-1).60 
These include injectable agents, older oral anticoagulants, and newer oral 
anticoagulants. A brief summary of the different pharmacological agents and their 
recommended dosage for VTE prophylaxis after replacement surgery is provided in 
Table 2-1. 
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Figure 2-1 Clotting cascade and mechanism of action of pharmacological agents 
 
Source: Sabir, et al.61 (Adapted) 
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Table 2-1 Pharmacological prophylaxis for VTE after replacement surgery 
Pharmacological agent Recommended dosing Duration 
Fondaparinux 2.5 mg/day, subcutaneously 
Started 6-8 hours after surgery 
28 days 
Unfractionated heparins 5,000 IU two to three times daily, 
subcutaneously or IV bolus 
Start preoperatively 
9 days or until 
hospital discharge 
LMWHs 
    Dalteparin 
 
 
    Enoxaparin 
 
    Tinzaparin 
 
 
 
5,000 IU daily, subcutaneously 
Start preoperatively, up to 2 hours 
before surgery 
 
30 mg twice daily, subcutaneously 
Start up to 12 hours before surgery 
 
3500 IU daily, subcutaneously 
 
 
9 days or until 
hospital discharge 
 
 
28 days 
Warfarin 2-5 mg daily, orally 
Adjusted to target INR of 2.0-3.0 
21 days or until 
hospital discharge 
Rivaroxaban 10 mg daily, orally 
Started 6-10 hours after surgery 
12-14 days for TKR  
35 days for THR 
Dabigatran 220 mg daily, orally  
150 mg daily, orally if age>75 
Started 1-4 hours after surgery 
10 days for TKR  
28-35 days for THR 
Apixaban 2.5 mg twice daily, orally 
Started 12-24 hours after surgery 
12 days for TKR 
35 days for THR 
 
*IU- international unit, IV- intravenous, LMWHs – low molecular weight heparins, INR- 
international normalized ratio, TKR- total knee replacement, THR- total hip replacement 
 
Source: Gross, et al.62 (Adapted) 
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Injectable agents mainly include fondaparinux and heparins – particularly 
unfractionated heparin (UFH) and low molecular weight heparins (LMWH).5 
Fondaparinux is an indirect inhibitor of the clotting factor Xa.63 It is administered 
subcutaneously about 6-8 hours after surgery as a daily dose of 2.5 milligrams. Some 
studies suggest that fondaparinux is more effective than LMWHs in preventing VTE 
after hip and knee replacements.64,65 However, its use may be associated with an 
increased risk of bleeding.64 Moreover, the subcutaneous administration of fondaparinux 
on a daily basis can be painful and can lead to non-compliance with the therapy.66 UFH 
is administered intravenously or subcutaneously a few hours before surgery and every 
8-12 hours for VTE prophylaxis after surgery. It is typically only used while the patient is 
in the hospital because it requires continuous monitoring and dosing adjustments due to 
inter-patient variability in dose response and changes in patient response over time.67-69  
LMWHs are more effective than UFH in VTE prophylaxis and have better 
bioavailability, longer half-life, and predictable dose-response relationship.67,70 Because 
of these clinical advantages, LMWHs have gradually replaced UFH for most 
indications.67 Heparins are inexpensive and effective in preventing VTE after surgery.67 
However, patients on heparin may experience some serious side effects, including 
heparin-induced thrombocytopenia, bleeding, renal failure, low blood platelets, and pain 
at the injection site. Heparin-induced thrombocytopenia is caused by the formation of 
abnormal antibodies after heparin administration which activates platelets resulting in 
the formation of blood clots. These blood clots can travel through the blood stream and 
increase the risk of VTE and stroke. 68 Like all other injectable agents, the main 
disadvantage of heparins is the inconvenience in route of administration and poor 
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patient compliance. Compliance with therapy is especially challenging after patients are 
discharged from the hospital.71 This is particularly concerning because most venous 
thrombotic events manifest clinically after discharge from the hospital.72,73 
 Oral anticoagulants offer the benefit of ease of administration over injectable 
agents and are preferable in patients experiencing difficulty in self-administration. Oral 
anticoagulants can be broadly classified as older oral anticoagulants (OACs) and newer 
or novel oral anticoagulants (NOACs). Warfarin is the most commonly used older oral 
anticoagulants. Warfarin indirectly inhibits various blood clotting factors (factors II, VII, 
IX, X, and proteins C and S) through vitamin K epoxide reductase complex subunit 1. It 
does not act on the circulating clotting factors, but rather on their synthesis in the liver, 
explaining its delayed effect. Although effective in preventing VTE, warfarin has several 
drawbacks. Warfarin has a narrow therapeutic index, requiring frequent dose 
adjustments. Variations in patient genotype have also been shown to affect warfarin 
dose requirements.16 In addition, warfarin is highly susceptible to interactions with 
prescription and non-prescription drugs, herbal and other natural products, as well as 
food and alcohol.74  Therefore, warfarin dose and its therapeutic effect must be 
determined by frequent laboratory monitoring of prothrombin time, expressed as 
international normalized ratio (INR). This can be expensive and time consuming. 
Warfarin therapy is also associated with bleeding complications.16 If started too close to 
surgery or at a higher dose, there is an increased risk of bleeding. However, if started 
too late and at a lower dose, there is an interval of unprotected time during which the 
patient is susceptible to VTE.45  
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The new oral anticoagulants, which include rivaroxaban, dabigatran, and 
apixaban, are poised to simplify the treatment of venous thromboembolism by 
eliminating the need for initial parenteral anticoagulant therapy and laboratory 
monitoring. In July 2011, rivaroxaban (Xarelto®) was the first novel oral anticoagulant 
that was approved by the FDA to reduce the risk of VTE from occurring after knee or hip 
replacement surgery. Soon after, in March 2014 and April 2014, respectively, apixaban 
(Eliquis®) and dabigatran (Pradaxa®) also received FDA approval for VTE prophylaxis 
in patients with arthroplasty. New oral anticoagulants act by inhibiting factor Xa or 
thrombin and have a rapid onset of action.75 Peak plasma levels are achieved within 1 
to 4 hours after oral administration, thereby eliminating the need for a parenteral 
anticoagulant. They also have a wide therapeutic window, little or no interaction with 
food and other drugs, minimal inter-patient variability, and display similar 
pharmacokinetics in different patient populations. The convenience of the new OACs 
has translated into improvements in efficacy and safety as shown in phase III 
randomized trials.  
2.4 Current evidence on the safety and efficacy of anticoagulants in management 
of venous thromboembolism in orthopedic surgery patients  
Two important factors that are considered when selecting anticoagulant therapy 
are their effectiveness and safety. Clinicians weigh in the benefits and risks of different 
anticoagulants and the patient’s medical history when initiating anticoagulants and 
selecting the type of anticoagulant.76 Effectiveness is a measure of preventing VTE 
events after initiating anticoagulant therapy. The main safety concern for anticoagulants 
is the risk of bleeding, especially major bleeding, intracranial hemorrhage and 
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gastrointestinal bleeding. Some surgeons are also concerned with an increased risk of 
peri-prosthetic infection with the use of anticoagulants.77  
Before the introduction of oral anticoagulants, low molecular weight heparins 
(LMWHs) have been the standard of care for patients undergoing orthopedic surgery.78 
A systematic review of randomized controlled trials demonstrated that LMWHs reduce 
symptomatic deep vein thrombosis (RR, 0.80; 95% CI, 0.73-0.88) without increasing the 
risk of major bleeding when compared with unfractionated heparins (RR, 0.91; 95% CI, 
0.75-1.09).79  The pooled result of clinical trials comparing LMWHs and fondaparinux 
failed to demonstrate or exclude a beneficial or detrimental effect of fondaparinux on the 
event rate of pulmonary embolism (RR, 1.32; 95%, 0.37-4.74) or deep vein thrombosis 
(RR, 1.31; 95% CI, 0.47-3.7). However, there was a statistically significant increase in 
the rate of hemorrhagic events (RR, 1.85; 95 % CI, 1.1-3.11) with use of fondaparinux 
compared to LMWHs.79 When LMWHs were compared to warfarin, the pooled result of 
clinical trials demonstrated that LMWHs significantly reduced the risk of symptomatic 
deep vein thrombosis (RR, 0.68; 95 % CI, 0.6-0.78), but also increased the risk of major 
bleeding (RR, 1.56; 95% CI, 1.23-2.0). However, while none of the hemorrhagic events 
in the LMWH group were fatal, there were two fatal bleeding events in the warfarin 
group which raises the safety concerns with warfarin therapy.79 
Various phase III trials have compared the effectiveness and safety of new oral 
anticoagulants. Four large phase III trials were conducted to compare rivaroxaban and 
enoxaparin in patients who had total hip replacement and total knee replacement 
surgery. Rivaroxaban (10 mg once daily) demonstrated superiority in reducing VTE after 
hip arthroplasty compared with enoxaparin (40 mg once daily) and a similar bleeding-
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event profile to that of enoxaparin in both, RECORD 1 and 2 studies.23,80 RECORD 2 
and 3 trials compared the efficacy of rivaroxaban after knee replacement surgery and 
also demonstrated superiority compared to enoxaparin (40 mg once daily-RECORD 3) 
and enoxaparin (30 mg twice daily-RECORD 4).81,82 Rates of bleeding events were the 
same in both groups in RECORD 3 and higher with rivaroxaban, but not statistically 
significant in RECORD 4 study.81,82 
The utility of dabigatran for VTE prophylaxis after hip or knee replacement has 
been investigated in four phase III studies. Dabigatran (150 mg or 220 mg once daily) 
demonstrated non-inferior efficacy and a similar safety profile to enoxaparin (40 mg 
once daily) for 28 to 35 days after THR (total hip replacement) surgery in RE-NOVATE 
and RE-NOVATE II and for 6 to 10 days after TKR (total knee replacement) surgery in 
RE-MODEL.25,27,83 There was no significant difference in the rates of major bleeding 
between the treatment groups in either study for dabigatran 150 mg once daily, 
dabigatran 220 mg once daily, and enoxaparin 40 mg once daily, respectively:25,27 
Three phase III trials investigated apixaban in patients who had total hip 
replacement or total knee replacement surgery. In the ADVANCE-2 and ADVANCE-3 
trials, apixaban (2.5 mg twice daily) demonstrated superiority in reducing the number of 
VTE events compared with enoxaparin (40 mg once daily) in patients who had 
undergone total knee replacement and total hip replacement surgery, respectively.28,29 
As with dabigatran in RE-MOBILIZE, however, apixaban (2.5 mg twice daily) failed to 
demonstrate non-inferiority to enoxaparin (30 mg twice daily) in ADVANCE-1.30 
Apixaban was not associated with increased rates of major bleeding events, compared 
with enoxaparin, in any of the three studies.28-30 
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2.5 Research Gap  
 Although randomized controlled trials are considered the “gold standard” in 
establishing efficacy of pharmacological agents, practitioners often require evidence of 
comparative effectiveness using observational data for understanding and establishing 
treatment recommendations in populations beyond the clinical trials.34,84 Randomized 
controlled trials are conducted in a very controlled and monitored setting, meaning their 
findings may not always reflect the same effect in real life.84 Patients enrolled in the 
RCTs may not be a true representative of the actual population and may not represent 
variation in the length of therapy, follow up time, or physician practice. For example, 
older patients were often excluded from RCTs of novel oral anticoagulants. Given the 
variation in patient population, route of administration and burden associated with 
treatment regimens, conducting an observational study to compare the effectiveness of 
available anticoagulants is itself a novel element. This is especially important in VTE 
prophylactic agents like warfarin, in which the safety and effectiveness of the therapy is 
dependent on adherence to therapy, diet, and INR monitoring.85 In warfarin patients, the 
percentage of time within therapeutic range (TTR) has been shown to strongly correlate 
with clinical outcomes.86 And although there is lack of real world data on time spent in 
therapeutic range for warfarin patients after major orthopedic surgery, estimates of TTR 
in atrial fibrillation patients show that the mean time in TTR is only 48% in the first six 
months of starting therapy.87 This is significantly lower than that observed for warfarin 
patients in the clinical trials for newer oral anticoagulants and can affect the real world 
effectiveness of warfarin therapy.88,89 Similarly, with injectable agents like heparins, the 
real world compliance and effectiveness of standard anticoagulants could be different 
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compared to randomized controlled trials which require complete compliance with 
therapy.33  No published literature has reported the real world effectiveness and safety 
of newer oral anticoagulants with standard anticoagulation therapies in patients with hip 
and knee replacement surgery.  
Furthermore, the phase III trials assessing efficacy and safety of newer oral 
anticoagulants among total knee and hip arthroplasty patients were mostly based on 10-
14 days, and in one study, up to 35 days of anticoagulation.21,23-25,27,80,90 However, 
research suggests that the risk of VTE persists for up to 3 months after surgery.91 There 
is no clear evidence on how long a patient undergoing hip and knee replacement 
surgery is anticoagulated with newer OACs in actual practice and what are the risks and 
benefits with varying the length of therapy. Understanding the real-world safety and 
effectiveness could help establish guideline recommendations through the use of 
targeted interventions to increase the effectiveness of pharmacological agents.   
There are also considerable gaps in literature related to safety of anticoagulants. 
Although the clinical trials for newer oral anticoagulants reported the risk of bleeding, it 
is not possible to compare safety data from trial to trial because there is no standardized 
definition of bleeding that has been used uniformly in all randomized controlled trials. 
Differences in reported major bleeding rates among pivotal trials for various 
anticoagulant agents are driven to a large extent by the actual definitions of bleeding, 
which were much stricter and limited in scope in the RECORD trials, driven partially by 
the regimens utilized and partially by the properties of the agents themselves. 
Furthermore, although reported as a concern by orthopedic surgeons, the differential 
risk for peri-prosthetic infection between anticoagulants has not been studied before. 
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Our study hopes to fill some of these gaps in literature by using real-world healthcare 
data. 
2.6 Significance of this research  
Randomized controlled trials often do not adequately reflect patient heterogeneity 
due to selective inclusion criteria, and therefore fall short of informing “real-world” 
clinical practice. Randomized controlled trials also may not represent variation in the 
length of therapy, follow up time, or physician practice. Given the variation in route of 
administration and burden associated with treatment regimens, conducting an 
observational study to compare the real-world effectiveness and safety of available 
anticoagulants is important. There are currently no observational studies that have used 
real world data to compare the effectiveness and safety of new OACs in the prevention 
of VTE in patients with orthopedic surgery.  Recently, use of electronic medical records 
and large healthcare databases has gained importance to assess real-world 
comparative effectiveness. In this study, we will explore the real world effectiveness and 
safety of anticoagulants using a claims database. We will use a retrospective cohort 
study design, which is the strongest study design, to establish casual inference when 
observational data is used.92 This dissertation will use the data from administrative 
claims submitted from health plans which have contracts with large private employers or 
with public organizations in the United States for the years between 2010 and 2016. 
The use of this recent data from the “real-world” will strengthen the external validity of 
the study by inclusion of patients with multiple comorbid conditions in the study cohort, 
which cannot be achieved through RCTs.   
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Results from our specific aim 1 may be useful in accessing and targeting the 
most important factors that facilitate anticoagulant treatment initiation. Results from 
Specific Aims 2 and 3 may help in guiding therapeutic decision-making to improve the 
quality of care provided to patients with orthopedic surgery. 
2.7 Conceptual Model 
 The following section describes the theoretical framework used to guide this 
dissertation by identifying factors that contribute to utilization of anticoagulants.  A 
conceptual model forms the basis for consideration of appropriate variables in any 
research study. The proposed conceptual framework for this dissertation was adapted 
from Andersen’s Emerging Behavioral Model of Health Services Use.93  According to 
the model, the use of healthcare services and subsequent health outcomes are 
influenced by a set of population characteristics. More specifically, these characteristics 
are divided into three groups: 1) predisposing factors, 2) need factors, and 3) enabling 
factors. Predisposing factors include patient characteristics that predispose them to the 
utilization of health services (e.g. race, age, gender, geographical factors). Need factors 
represent both the perceived and the actual health state of patients that necessitate the 
utilization of health services (e.g. comorbid conditions, severity of illness, use of other 
medications). Enabling factors include variables representing patients’ ability to secure 
the healthcare services (e.g. health insurance type, prescription drug coverage 
generosity).  
Based on these principles, this model was adapted to fit our research needs. 
Figure 2-2 shows Andersen’s model with our variables of interest.  
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Figure 2-2 Andersen’s Emerging Behavioral Model of Health Services Use 
(Adapted) 
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predisposing factors in our model. Some studies suggest that the risk of intracranial 
hemorrhage increases with age in warfarin patients.94,95 This could affect the 
prescription of warfarin in older patients. Clinicians might be more likely to prescribe 
relatively safer-perceived anticoagulants such as LMWHs for older patients. The 
incidence of VTE is higher in elderly men compared to women which could result in 
different gender-based anticoagulant prescribing patterns.96,97 Similarly, geographic 
variation has been reported in the risk of VTE. 98 Patients residing at higher altitudes 
have a reported predisposition for hypercoagulable state and are at an increased risk 
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for VTE. Based on regional differences, prescribing patterns may vary which will be 
explored in our model. We also included the year of surgery as a variable in our model 
because prescription patterns change over time, especially with the introduction of new 
therapies, availability of new clinical information, and change in therapeutic 
guidelines.99-101 
Enabling factors are factors that facilitate obtaining health care.  In our model, we 
translated this into an individual’s ability to obtain the more expensive, newer oral 
anticoagulants.  A study reported that privately insured patients or patients with a higher 
insurance index are more likely to receive new drugs than others.102 We examined this 
association in our model and its effect on the type of anticoagulant received by including 
the type of health benefit plan and prescription drug benefit generosity index in the 
model. We hypothesized that patients with more generous prescription drug benefit will 
be more likely prescribed one of the newer oral anticoagulants over warfarin.  
Need based factors are clinical factors that necessitate the utilization of health 
care services. Bleeding risk is often weighed along with a concurrent VTE risk 
assessment in deciding the choice of anticoagulant. We included known risk factors for 
bleeding and VTE as the clinical need factors in the model such as past clinical events, 
comorbidities and concurrent therapy.  Comorbidities and past clinical events such as 
previous venous thromboembolism (VTE), ischemic stroke, and acute myocardial 
infarction (AMI) are considered risk factors for VTE and were included in the model.110 
Bleeding risk is often weighed along with a concurrent VTE risk assessment and 
presence of any previous major bleeding event was included in the model. Bleeding risk 
may be increased by surgery, medications, or factors inherent to the patient. A recent 
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observational study by the IMPROVE investigators reported on factors found to be most 
predictive of in-hospital bleeding in medical patients.61 Active peptic ulcer, active 
bleeding within 3 months prior to admission, hepatic failure, age ≥85 years, and male 
gender were the strongest independent risk factors. We included these variables along 
with presence of gastritis, esophagitis, and duodenitis which are also known risk 
factors111 for bleeding in the model. Other patient comorbidities including diabetes 
mellitus, atrial fibrillation, congestive heart failure (CHF), cardiovascular diseases, 
hypertension, hyperlipidemia, renal impairment, sleep apnea, cancer, dementia and 
anemia are also associated with the choice of anticoagulants in patients with atrial 
fibrillation and were also included in our model.103 Body mass index is also a known 
predictor of choice of anticoagulant therapy. However due to the nature of 
administrative claims data, we did not have access to this information. We used 
clinically diagnosed obesity as a proxy for body mass index. Concomitant therapies 
including antiplatelet therapy, antiarrhythmics, rate control therapies (eg, digoxin, beta‐
blockers, calcium channel blockers), statins, gastroprotective agents, ACE inhibitors, 
and hormonal contraceptives  are contraindicated in certain anticoagulants104 and can 
affect the choice of anticoagulant prescribed. Concomitant use of these medications  
with the anticoagulant was also included in the model. The Charlson Comorbidity Index 
(CCI) is a commonly-used composite measure of overall disease burden which serves 
as a proxy for patient health status; the higher the score, the greater the comorbidity 
burden.115, 116 The CCI algorithm using ICD-9 codes has been previously published in a 
variety of settings and was employed to garner patient baseline disease burden.105-107 
We also included hospitalization and the type of surgery setting (outpatient vs. inpatient) 
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in the model. All the covariates were measured in the 180 days baseline period. We 
assessed the association of baseline covariates and the choice of anticoagulant using 
logistic regression model. 
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Chapter 3 : METHODS 
 
 
In section 3.1, the data source used for this dissertation is described. In section 3.2, 
methods used are described in detail by specific aims and finally in section 3.3, issues 
related to statistical power are discussed.  
3.1 Data Source 
 The Truven Health MarketScan Commercial Claims and Encounters (CCAE) and 
Medicare Supplemental and Coordination of Benefits (COB) data were used for this 
study. The Truven MarketScan database contains de-identified patient level information 
on health care utilization, health care expenditure, insurance enrollment and plan 
benefit for commercially insured patients and Medicare-eligible retirees. The CCAE 
database consists of employer and health plan sourced data containing medical and 
prescription drug claims from over 100 nationwide insurers for around 40 million 
individuals annually. Enrollees include active employees, their spouses, early retirees, 
COBRA continuees, and their dependents insured by employer-sponsored private 
health insurance plans (ie, non-Medicare eligibles). Healthcare for these individuals is 
provided under a variety of fee-for-service (FFS), fully capitated, and partially capitated 
health plans, including preferred and exclusive provider organizations (PPOs and 
EPOs), point of service (POS) plans, indemnity plans, and health maintenance 
organizations (HMOs).  
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The MarketScan Medicare Supplemental and Coordination of Benefits (Medicare 
Supplemental) database contains claims data for Medicare-eligible retirees with 
supplemental insurance plans offered by their former employers. There are 
approximately 4.3 million enrollees annually included in the database. The Medicare 
Supplemental Database provides detailed utilization and health outcomes (e.g. adverse 
events) data for healthcare services performed in both, the inpatient and outpatient 
settings. Beneficiaries in the MarketScan Medicare database also have drug coverage; 
and therefore provide additional valuable information. Claims include the Medicare-
covered portion of payment (represented as Coordination of Benefits Amount, or COB).  
Both databases include patient specific inpatient and outpatient service claims, 
physician office visits, outpatient prescription drug and enrollment information. 
Additionally, the data can be linked to track detailed patient information across sites, 
types of providers, and over time thereby reflecting a true continuum of care.108 Due to 
its substantial size, longitudinal integrity, and unique data links, this database provides 
an ideal opportunity to conduct pharmacoepidemiologic research. In this particular 
analysis, data from inpatient services file, outpatient services file, prescription drug 
claims file and enrollment file were merged using unique patient identifiers. 
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3.2 Methods by Specific Aim 
The plan for patient population, study design, measurement of variables and statistical 
analyses is detailed below by Specific Aim. 
 
3.2.1 Specific Aim 1a: To analyze market trends in the utilization of anticoagulants 
in patients undergoing an elective total hip or knee replacement surgery. 
Study population 
Time frame for the trend analysis was from January 1, 2010 to December 31, 
2015. We chose this time frame to analyze the change in utilization of anticoagulants 
after the introduction of novel oral anticoagulants to the US market. Dabigatran was the 
first non-Vitamin K oral anticoagulant approved by the US FDA on October 19, 2010. 
However, it was approved for stroke prevention indication in patients with atrial 
fibrillation. On November 23, 2015, dabigatran received approved for VTE prevention 
after hip replacement surgery. Rivaroxaban was the first approved novel oral 
anticoagulant for VTE prophylaxis after knee and hip replacement surgeries and 
received FDA approval on July 1, 2011. Apixaban was introduced to the US market on 
December 28, 2012, but received approval for VTE prophylaxis indication following hip 
and knee replacement surgery on March 18, 2014. 
Patients undergoing a total knee replacement surgery or a total hip replacement 
surgery during the study period were identified using inpatient and outpatient claims 
data. International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-
9-CM) codes, International Classification of Diseases, Tenth Revision, Procedure 
Coding System (ICD-10-PCS) and Current Procedural Terminology (CPT) medical 
billing codes were used to identify total hip replacement and total knee replacement and 
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are reported in table 3-1. We extracted and analyzed their prescription drug claims data 
for an anticoagulant prescription fill from seven days before their surgery date until three 
months after their surgery date. A seven-day pre-surgery period was used to identify 
patients that could have filled the prescription in preparation for their surgery. National 
drug codes (NDCs) were used to identify the different types of anticoagulants. These 
were categorized as low molecular weight heparins, warfarin, dabigatran, rivaroxaban, 
and apixaban. We analyzed quarterly prescription volumes in patients undergoing 
surgery from January 2010 to December 2015 to understand patterns in treatment 
utilization. A quarter was defined as a three-month interval. Prescription volume 
included new fills for these medications during the three-month post-surgery window. 
We segregated the analysis by the type of surgery – total hip replacement or total knee 
replacement, and the type of insurance – commercially insured cohort and Medicare 
cohort due to the inherent differences in these populations. 
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Table 3-1 Procedure codes for elective total hip and knee replacement surgery 
ICD-9 CM  ICD – 10 PCS CPT code Category description 
81.51   Total hip replacement 
 0SR90J9  Replacement of Right Hip Joint with 
Synthetic Substitute, Cemented, Open 
Approach 
 0SR90JA  Replacement of Right Hip Joint with 
Synthetic Substitute, Uncemented, Open 
Approach 
 0SR90JZ  Replacement of Right Hip Joint with 
Synthetic Substitute, Open Approach 
 0SRB0J9  Replacement of Left Hip Joint with Synthetic 
Substitute, Cemented, Open Approach 
 0SRB0JA  Replacement of Left Hip Joint with Synthetic 
Substitute, Uncemented, Open Approach 
 0SRB0JZ  Replacement of Left Hip Joint with Synthetic 
Substitute, Open Approach 
  27130 Arthroplasty, acetabular and proximal 
femoral prosthetic replacement (total hip 
arthroplasty), with or without autograft or 
allograft 
81.54   Total knee replacement 
 0SRC07Z  Replacement of Right Knee Joint with 
Autologous Tissue Substitute, Open 
Approach 
 0SRC0JZ  Replacement of Right Knee Joint with 
Synthetic Substitute, Open Approach 
 0SRC0J9  Replacement of Right Knee Joint with 
Synthetic Substitute, Open Approach, 
Cemented 
 0SRC0KZ  Replacement of Right Knee Joint with 
Nonautologous Tissue Substitute, Open 
Approach 
 0SRC0LZ  Replacement of Right Knee Joint with 
Unicondylar Synthetic Substitute, Open 
Approach 
 0SRD07Z  Replacement of Left Knee Joint with 
Autologous Tissue Substitute, Open 
Approach 
 0SRD0JZ  Replacement of Left Knee Joint with 
Synthetic Substitute, Open Approach 
 0SRD0J9  Replacement of Left Knee Joint with 
Synthetic Substitute, Open Approach, 
Cemented 
 0SRD0KZ  Replacement of Left Knee Joint with 
Nonautologous Tissue Substitute, Open 
Approach 
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 0SRD0LZ  Replacement of Left Knee Joint with 
Unicondylar Synthetic Substitute, Open 
Approach 
 0SRT07Z  Replacement of Right Knee Joint, Femoral 
Surface with Autologous Tissue Substitute, 
Open Approach 
 0SRT0JZ  Replacement of Right Knee Joint, Femoral 
Surface with Synthetic Substitute, Open 
Approach 
 0SRT0KZ  Replacement of Right Knee Joint, Femoral 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
 0SRU07Z  Replacement of Left Knee Joint, Femoral 
Surface with Autologous Tissue Substitute, 
Open Approach 
 0SRU0JZ  Replacement of Left Knee Joint, Femoral 
Surface with Synthetic Substitute, Open 
Approach 
 0SRU0KZ  Replacement of Left Knee Joint, Femoral 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
 0SRV07Z  Replacement of Right Knee Joint, Tibial 
Surface with Autologous Tissue Substitute, 
Open Approach 
 0SRV0JZ  Replacement of Right Knee Joint, Tibial 
Surface with Synthetic Substitute, Open 
Approach 
 0SRV0KZ  Replacement of Right Knee Joint, Tibial 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
 0SRW07Z  Replacement of Left Knee Joint, Tibial 
Surface with Autologous Tissue Substitute, 
Open Approach 
 0SRW0JZ  Replacement of Left Knee Joint, Tibial 
Surface with Synthetic Substitute, Open 
Approach 
 0SRW0KZ  Replacement of Left Knee Joint, Tibial 
Surface with Nonautologous Tissue 
Substitute, Open Approach 
  27447 Arthroplasty, knee, condyle and plateau; 
medial and lateral compartments with or 
without patella resurfacing (total knee 
arthroplasty) 
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3.2.1.b Specific Aim 1b: To identify factors influencing the choice of 
anticoagulation therapy in patients undergoing an elective total hip or knee 
replacement surgery. 
Patient population 
The time frame for our study was from January 1, 2011 to December 31, 2015. 
This time frame was selected because the first newer oral anticoagulant, dabigatran, 
was approved in United States by the Food and Drug Administration (FDA) on October 
19, 2010. To allow for 180 days of baseline and at least 90 days of follow up period for 
everyone, the subject identification period started from July 1, 2011 and ended on 
September 1, 2015. Patients undergoing a total hip replacement (THR) or a total knee 
replacement (TKR) surgery during this time period were eligible for inclusion in the 
cohort. We built four separate cohorts based on the type of surgery and type of 
insurance: (1) commercially insured total hip replacement patients, (2) Medicare total 
hip replacement patients, (3) commercially insured total knee replacement patients, and 
(4) Medicare total knee replacement patients. The patient population was separated 
accordingly because the risk of outcomes was assumed to be different in each of these 
cohorts due to inherent baseline differences in these cohorts. Total knee replacement 
and total hip replacement were identified by an inpatient or outpatient claim using 
medical billing codes as described in table 3-1. These operational definitions to identify 
TKR and THR are based on previously published literature and mapped to include ICD-
10 PCS.109,110 The date of discharge from hospital was considered as the index date. 
 Patients younger than 18 years were excluded from this study because hip or 
knee replacement under 18 years is generally due to trauma induced injuries and differs 
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systematically from total joint replacement in regards with disease progression and 
treatment. We further limited the inclusion to patients continuously enrolled in their 
health plan for at least 180 days prior to and 90 days after their index date. This was 
done because intermittent enrollment may result in incompleteness of the data in our 
analytic dataset; which in turn could lead to misinterpretation of our effect estimates. 
The 180 days of continuous enrollment period prior to the index date was defined as the 
baseline period. In addition, patients were excluded from the study if they had an 
anticoagulant prescription fill in the baseline period until seven days prior to the surgery 
to examine new users of anticoagulation. We excluded prevalent users because if the 
hazard function associated with the use of anticoagulants varies with time, it can 
introduce substantial bias. However, we restricted this criterion to seven days before the 
surgery due to the assumption that treatment-naïve patients that filled the anticoagulant 
prescription just prior to surgery were most likely filling it for use after surgery. The effect 
of this assumption was further explored by running a sensitivity analysis for dates of fill 
around the surgery date. We also excluded patients who had a previous major 
orthopedic surgery in the baseline period to avoid potential confounding factors 
associated with previous surgeries and medication use. Figure 3-1 summarizes the 
inclusion and exclusion criteria for our study cohort. 
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Figure 3-1  Inclusion-exclusion criteria for aim 1b 
 
 
 
Total joint replacement identification: THR or TKR diagnosis (using ICD 9 
CM, ICD 10 PCS and CPT codes) recorded on either inpatient or outpatient 
service claims between July 1, 2011 to September 30, 2015 
(4 cohorts: commercially insured THR, Medicare THR, commercially 
insured TKR, Medicare TKR 
Exclude: Age < 18, not continuously 
enrolled  
Eligibility requirements: Patients >18 yrs with 210 days continuous 
enrollment (180 days pre-index + 90 days post-index) in their health plan  
 
 
Patients using rivaroxaban or warfarin following surgery 
New users of anticoagulants following surgery 
Final sample 
 
Exclude: Patients not on warfarin or 
rivaroxaban or using multiple 
anticoagulants following surgery 
Exclude: Prevalent users of rivaroxaban or 
warfarin 
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Study design 
We designed a retrospective cohort study to evaluate factors influencing the 
choice of anticoagulant for this particular aim. Patients included in the study cohort (See 
Figure 3-1) were followed for 30 days from the index date for determining anticoagulant 
treatment exposure. Figure 3-2 shows a schematic diagram of study design for aim 1. 
 
Figure 3-2 Study design for Aim 1 
 
Measurement of variables 
Covariates: In this specific aim, we evaluated factors influencing the choice of 
anticoagulant treatment in total joint replacement surgery patients (Table 3-2). All the 
patient factors were independent variables of interest and were measured during the 
180 days baseline period preceding their index date.   
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Table 3-2 Covariate descriptions and coding strategies for patient characteristics 
in baseline period 
Patient Characteristics Covariate Coding Covariate Definition 
Predisposing Characteristics  
Age at the time of surgery Continuous Age in years at time of 
orthopedic surgery 
Sex 1=Male, 2=Female 
 
Sex from enrollment file 
Geographic Region 1=Northeast, 2=North central, 
3= South, 4=West, 
5=Unknown 
Region from enrollment file 
Metropolitan statistical area 
indicator 
First three digits of zip code  Three digit zip code 
indicator from enrollment file 
Time of surgery Year of surgery Year of surgery from 
inpatient file 
Enabling Resources   
Type of health benefit plan 1=Basic/major medical 
2=Comprehensive 
3=EPO 
4=HMO 
5=POS 
6=PPO 
7=POS with capitation 
8=CDHP 
9=HDHP 
 
Type of health benefit plan 
from enrollment file 
Prescription benefits 
generosity 
1=No/Poor coverage 
2=Fair coverage 
3=Good coverage 
4=Unknown 
Ratio of patient cost-sharing 
for prescription payments 
relative to total payments for 
prescriptions 
Need Characteristics   
Past clinical events   
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Previous venous 
thromboembolism (VTE)  
0=Absent, 1=Present VTE diagnosis  
Previous ischemic stroke 0=Absent, 1=Present Ischemic stroke diagnosis 
Previous myocardial infarction 0=Absent, 1=Present Myocardial infarction 
diagnosis 
Previous major bleeding 0=Absent, 1=Present Diagnosis of hemorrhagic or 
gastrointestinal bleeding 
Comorbidities   
Charlson Comorbidity Index 
(CCI) 
Categorical (0, 1, 2-4, ≥5) Patient disease severity 
Atrial Fibrillation 0=Absent, 1=Present Atrial fibrillation diagnosis 
Cardiovascular disease 0=Absent, 1=Present Cardiovascular disease 
diagnosis 
Congestive Heart Failure 0=Absent, 1=Present Congestive heart failure 
diagnosis 
Hepatic failure 0=Absent, 1=Present Liver failure diagnosis 
Renal Impairment 0=Absent, 1=Present Chronic kidney disease or 
End Stage Renal Disease 
diagnosis 
Peptic Ulcer disease 0=Absent, 1=Present Diagnosis of peptic ulcer 
disease 
Gastritis 0=Absent, 1=Present Diagnosis of gastritis 
Duodeniitis 0=Absent, 1=Present Diagnosis of duodenitis 
Esophagitis 0=Absent, 1=Present Diagnosis of esophagitis 
Hyperlipidemia 0=Absent, 1=Present Hyperlipidemia diagnosis 
Hypertension 0=Absent, 1=Present Hypertension diagnosis 
Diabetes Mellitus 0=Absent, 1=Present Diabetes Mellitus diagnosis 
Anemia 0=Absent, 1=Present Diagnosis of anemia 
Sleep apnea 0=Absent, 1=Present Diagnosis of sleep apnea 
Cancer 0=Absent, 1=Present Diagnosis of cancer 
Dementia 0=Absent, 1=Present Diagnosis of dementia 
Obesity 0=Absent, 1=Present Diagnosis of obesity 
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Number of hospitalizations Categorical (0, ≥1) Number of hospitalizations in 
baseline 
Type of Surgery Setting 0=Outpatient procedure, 
1=Inpatient procedure 
Type of surgery setting 
Concomitant therapies  
Antiplatelet therapy (aspirin 
excluded) 
0=Non-use, 1=Use Prescription fill for 
clopidogrel or Aggrenox  
Gastroprotective agents 0=Non-use, 1=Use Prescription fill for PPIs, 
H2RAs, GI protectants (e.g., 
sucralfate) 
Antiarrhythmics 0=Non-use, 1=Use Prescription fill for flecainide, 
amiodarone, dronedarone, 
sotalol, propafenone and 
dofetilide 
Rate control therapy 0=Non-use, 1=Use Prescription fill for beta-
blockers, digoxin, or calcium 
channel blocker 
Hormonal contraceptive use 0=Non-use, 1=Use Prescription fill for oral 
contraceptive  
ACEI/ARB therapy 0=Non-use, 1=Use Prescription fill for ACEI/ARB 
Statin therapy 0=Non-use, 1=Use Prescription fill for HMG Co-
A-reductase (statin) 
  
The details of variables to be measured are provided below. 
1. Predisposing factors: Patients’ age on their index date was measured as a 
continuous variable. Proportions of male and female patients in each 
anticoagulant group were reported. Two variables for the geographic location 
were included, 1) geographic region, in which the patients were placed in one of 
the following groups based on US census region: Northeast, Midwest, South 
and West (Refer to Table 3-3 for the regional assignment) and 2) a metropolitan 
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statistical area indicator. The year of surgery was also included as a proxy for 
time. 
Table 3-3 Geographic Region Definitions 
Region States 
Northeast Connecticut, Maine, Massachusetts, New Hampshire, Vermont, 
Rhode Island, New Jersey, New York, and Pennsylvania 
Midwest Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas,  
Minnesota, Missouri, Nebraska, North Dakota, and South Dakota 
South Delaware, District of Columbia, Florida, Georgia, Maryland, North 
Carolina, South Carolina, Virginia, Alabama, Kentucky, Mississippi, 
Tennessee, West Virginia, Arkansas, Louisiana, Oklahoma, and 
Texas 
West Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, 
Wyoming, Alaska, California, Hawaii, Oregon, and Washington 
Source: http://www.census.gov/geo/www/geo_defn.html#GeographicCode 
 
2. Enabling factors: We included type of health benefit plan and a measure of the 
generosity of the prescription drug benefit as enabling factors.111  Type of health 
benefit plan was a categorical variable indicating capitated plans such as health 
maintenance organization, or point‐of‐service plans and non-capitated plans 
such as basic major medical, comprehensive, exclusive provider organization, 
preferred provider organization, non-capitated point‐of‐service, consumer‐driven 
health plan or high deductible health plan. Drug benefit generosity was 
approximated by creating a ‘generosity index’ using payment information from 
all the prescriptions filled by patients in the baseline period. This index was 
calculated as a continuous scale in the range of 0-1 and was defined as 
patients’ cost‐sharing proportions for all prescriptions in the baseline period prior 
to anticoagulant initiation divided by the total net drug payments as a benefits’ 
generosity measure. Based on this index, patients were classified into three 
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ratio levels of drug benefit generosity to facilitate interpretation: >0.80 paid by 
patients (“No/Poor coverage”), 0.20 to 0.80 (“Fair coverage), and ≤0.20 (“Good 
coverage”). Similar methods have been successfully used in prior studies.111 
Patients with prescription drug benefits but with no measured prescription fills in 
the baseline period were assigned an unknown status. We reported the number 
of patients with unknown information in prescription drug benefits. 
3. Clinical need factors: We measured the risk factors for VTE, patients’ 
comorbidity profile and concurrent therapy in the baseline period. Details for 
measurement are as follows, 
a. Past clinical events: Relevant clinical events were identified in the 180 
days baseline period using ICD‐9 and ICD-10 codes in the outpatient and 
inpatient medical claims files based on previous literature.105  These 
included known risk factors for VTE and bleeding such as previous 
venous thromboembolism, ischemic stroke, acute myocardial infarction 
(AMI), and bleeding 
b. Comorbidity profile:  Patient comorbidities including atrial fibrillation, 
cardiovascular diseases, diabetes mellitus, congestive heart failure 
(CHF), hypertension, hyperlipidemia, renal impairment, peptic ulcer 
disease, gastritis, duodenitis, esophagitis, hepatic failure, anemia, sleep 
apnea, obesity, cancer and dementia were also measured using ICD‐9 
and ICD-10 codes in the outpatient and inpatient medical claims files. 
Charlson’s comorbidity index was also calculated as an overall measure 
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of patient comorbidity burden. Previous hospitalization and setting of 
surgery was also included as covariates. 
c. Use of co-medications: We measured the utilization of concomitant 
therapies in the baseline period including antiplatelet therapy, 
antiarrhythmics, rate control therapies (eg, digoxin, beta‐blockers, 
calcium channel blockers), statins, gastroprotective agents, ACE 
inhibitors and hormonal contraceptives because of known associations 
with anticoagulation. These products were identified using the national 
drug code (NDC) numbers from the outpatient pharmacy files. 
 
Dependent (Outcome) variable: The outcome variable of interest was type of 
anticoagulant initiated during the 30 days of follow up period beginning on the index 
date or seven days in the pre-index period. Type of anticoagulant was categorized as 
warfarin and rivaroxaban. The use of these anticoagulants was identified using NDC 
numbers from outpatient pharmacy files for filled prescriptions. Patients who were 
exposed to more than one anticoagulant were excluded from the analysis.  
 
Statistical analysis 
Descriptive statistics were used to summarize and compare patient factors in 
warfarin and rivaroxaban users. For dichotomous and categorical variables, the results 
were presented as numbers and proportions. For continuous variables, the results were 
presented as mean (± SD). The patient factors were then compared between warfarin 
users and rivaroxaban users using standardized differences. This method was used to 
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avoid statistically significant but clinically meaningless differences between our two 
groups owing to the large sample size.   
The equation for standardized differences can be given as follows: 
 Standardized difference = Treatment improvement − Comparator improvement 
                                                            Pooled standard deviation  
Standardized difference of zero means that the treatment and the comparator 
have equivalent effects. Standardized differences greater than 0.2 mean smaller effect 
size; greater than 0.5 is considered medium and greater than 0.8 is considered a large 
effect.112 To understand the impact of various covariates on the choice of anticoagulant 
therapy, logistic regression models were used. Although a common approach to 
statistical model building is minimization of variables until the most parsimonious model 
is obtained, methodologists argue that it could lead to eliminating relevant confounders 
from the model as well as potentially overfitting the data.  To overcome this issue, some 
epidemiologists suggest inclusion of all clinical and other relevant variables in the model 
regardless of their significance in order to control for confounding. We used this 
approach to include all the relevant clinical and demographics variables that have been 
previously found to be associated with the choice of anticoagulant after a hip or knee 
replacement. 
The logistic regression equation used was:  
 
         = β0 + β1Χ1 + β2Χ2 + β3Χ3 +….βnΧn + ε  
 
y= type of anticoagulant treatment (warfarin or rivaroxaban) 
β=regression co-efficient for the independent variables  
           
 y
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X= Independent variable 
ε= error  
Sensitivity analysis: 
One of the limitations of including all theoretical confounders irrespective of their 
significance is that it can lead to numerically unstable estimates and large standard 
errors. To understand the effect of including such confounders in our model, we ran a 
sensitivity analysis to obtain the most parsimonious model through purposeful selection 
as suggested by Bursac et al.113 In this sensitivity analysis, we began the model building 
and variable selection by univariate analysis of each variable as previously identified. 
Any variable having a significant univariate test at p-value cut-off point of 0.25 was 
selected as a candidate to be included in the model. In the iterative process of variable 
selection, covariates were removed from the model if they were non-significant and not 
a confounder. Significance was evaluated at the 0.1 alpha level and confounding was 
defined as a change in any remaining parameter estimate greater than 15% as 
compared to the full model. These cut off ranges were based on the recommended 
values by the authors.113 A change in the parameter estimate above the specified level 
indicates that the excluded variable was important in providing a needed adjustment for 
one or more of the variables remaining in the model. At the end of this iterative process 
of deleting, refitting, and verifying, the model contained significant covariates and 
confounders. Any variable not selected for the original multivariate model was then 
added back one at a time, with significant covariates and confounders retained earlier. 
This step is helpful in identifying variables that, by themselves, are not significantly 
related to the outcome but make an important contribution in the presence of other 
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variables. Those that are significant at the 0.15 level were put in the model, and the 
model was iteratively reduced as before but only for the variables that were additionally 
added.  
 
3.2.2 Specific Aim 2: To compare the real world effectiveness of novel oral 
anticoagulant rivaroxaban with standard oral anticoagulant warfarin in venous 
thromboembolism prevention among patients with elective total hip or knee 
replacement surgery. 
 
Patient population and study design 
For this aim, we designed a retrospective cohort study to study the effectiveness 
of warfarin and rivaroxaban for VTE prevention in patients with total hip or knee 
replacement surgery.  All the patients identified as the members of the hip or knee 
replacement surgery population in aim 1 (figure 3-3) comprised of the base cohort for 
aim 2.  
Inclusion- exclusion criteria 
To be considered for the comparative effectiveness analysis, patients in the base 
cohort had to meet the following inclusion criteria:  
1) Patients with an inpatient or outpatient claim for an elective total hip replacement 
or elective total knee replacement surgery. 
2) At least 18 years of age at the time of the surgery 
3) Continuous enrollment in their health plans during the 180 days of the baseline 
period and 90 days post index period to ensure completeness of data 
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4) No use of any anticoagulants in the baseline period because when the risk of 
outcome is altered with the course of treatment, the internal validity of the study 
is compromised if we fail to account for duration of the treatment. This issue can 
be circumvented by exclusion of prevalent drug users and constructing a clean 
cohort of only the new drug users.114 
5) No previous history of hip or knee replacement surgery. We also excluded 
patients with partial hip or knee replacement surgery. 
 Follow up period was defined as the 90 day period following discharge after orthopedic 
surgery.  
 
 
  
Figure 3-3 Study design for Aim 2 
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Measurement of variables 
The outcome of interest was venous thromboembolism which was a measure of 
the occurrence of pulmonary embolism and deep vein thrombosis in the follow‐up 
period. Outcomes were assessed based on the presence of inpatient or outpatient 
claims with a primary diagnosis. Validated ICD‐9 coding algorithms (Table 3-4) and 
mapped ICD 10 codes were used to measure the outcome events, which are based on 
published studies found in the literature.115,116   
Table 3-4 Medical diagnosis codes for outcomes in aim 2 
ICD-9 CM  ICD – 10 PCS Category description 
451.1x  Phlebitis and thrombophlebitis of 
deep veins of lower extremities 
451.2  Phlebitis and thrombophlebitis 
of lower extremities unspecified 
453.4x  Acute venous embolism and thrombosis of 
deep vessels of lower extremity 
453.8  Acute venous embolism and thrombosis of 
other specified veins 
453.9  Embolism and thrombosis of unspecified site 
 I82.40X Acute embolism and thrombosis of 
unspecified deep veins of lower extremity 
 I82.401 Acute venous embolism and thrombosis of 
deep vessels of right lower extremity 
 I82.402 Acute venous embolism and thrombosis of 
deep vessels of left lower extremity 
 I82.403 Acute venous embolism and thrombosis of 
deep vessels of lower extremity, bilateral 
 I82.409 Acute venous embolism and thrombosis of 
deep vessels of unspecified lower extremities 
 I82.419 Acute embolism and thrombosis of 
unspecified femoral vein 
 I82.429 Acute embolism and thrombosis of 
unspecified iliac vein 
 I82.439 Acute embolism and thrombosis of 
unspecified popliteal vein 
 I82.4Y9 Acute embolism and thrombosis of 
unspecified proximal lower extremity 
 I82.449 Acute embolism and thrombosis of 
unspecified tibial vein 
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 I82.499 Acute embolism and thrombosis of other 
specified deep vein of unspecified lower 
extremity 
 I82.4Z9 Acute embolism and thrombosis of 
unspecified deep veins of unspecified distal 
lower extremity 
 I82.62X Acute embolism and thrombosis of deep 
veins of upper extremity 
 I82.621 Acute embolism and thrombosis of deep 
veins of right upper extremity 
 I82.622 Acute embolism and thrombosis of deep 
veins of left upper extremity 
 I82.623 Acute embolism and thrombosis of deep 
veins of upper extremity, bilateral 
 I82.629 Acute embolism and thrombosis of deep 
veins of unspecified upper extremity 
415.1x  Pulmonary embolism and infarction 
 I26.99 Acute pulmonary embolism 
 I26.01 Septic pulmonary embolism with acute cor 
pulmonale 
 I26.90 Septic pulmonary embolism without acute cor 
pulmonale 
 I26.02 Saddle embolus of pulmonary artery with 
acute cor pulmonale 
 I26.92 Saddle embolus of pulmonary artery without 
acute cor pulmonale 
 I26.09 Other pulmonary embolism with acute cor 
pulmonale 
 
Baseline covariates included in the propensity model were age, gender, year of 
surgery, census region of residence, type of health benefit plan, measure of the 
generosity of the prescription drug benefit, CCI, history of DVT or PE, ischemic stroke, 
myocardial infarction, atrial fibrillation, diabetes, dementia, hypertension, anemia, 
cardiovascular diseases, congestive heart failure, hepatic failure, renal impairment, 
sleep apnea, cancer, obesity, number of hospitalizations, type of surgery setting, 
antiplatelet therapy, antiarrythmics, rate control therapy, ACE inhibitors, hormone use 
and statins. The number of events in the follow up period were reported as VTE event 
rate.  
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Statistical analysis 
Descriptive statistics were generated including the VTE rates in each 
anticoagulant group and distributions of baseline characteristics. We estimated odds 
ratios (OR) and 95% confidence intervals (CIs) using logistic regression models with 
stabilized inverse probability treatment weighting (IPTW).117  IPTW was used to adjust 
for baseline differences among warfarin and rivaroxaban users.  
Inverse probability treatment weighting: 
Establishing causal inference using observational data is often disputed because 
the study subjects are not randomly allocated, which may result in selection bias. 
However, advanced techniques such as propensity score adjustment can be used to 
reduce these confounding biases.118 Propensity score (PS) methods attempt to control 
for lack of randomization in observational studies by balancing covariate distributions 
between treatment groups.118,119  Estimates of the average treatment effect in the 
treated group can be obtained by PS matching between two comparable groups, such 
that pairs of matched individuals have similar values of the propensity score. Other 
options involving propensity scores are including the PS as a covariate in multivariable 
regression models, stratification, or using weighting through inverse-probability 
treatment weighting (IPTW). Our study will use IPTW to create a study sample whereby 
the distribution of measured baseline characteristics does not depend on treatment. In 
IPTW, each subject’s weight is equal to the inverse of the probability of receiving that 
particular treatment. We used the IPTW method because the number of warfarin users 
were almost the same as the number of rivaroxaban users. Regression models can be 
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weighted by the inverse probability of treatment to estimate the average treatment effect 
of receiving the treatment. 
 
Propensity score weights were estimated using logistic regression that included 
all variables identified from aim 1 as covariates. The propensity score distributions were 
examined by exposure status for overlap to assess factors associated with overall 
treatment selection and comparability of the covariate distributions. We then estimated 
the treatment effects using propensity score weighting, including IPTW approaches, 
trimming for non‐overlapping regions. Because weights may be unstable for individuals 
with very low probabilities of receiving treatment, stabilizing weights and ‘trimming’ 
subjects are methods often used. IPTW uses weights based on the propensity score to 
create a synthetic sample in which the distribution of measured baseline covariates is 
independent of treatment assignment. Weights are computed that denote the probability 
of receiving the treatment that was actually received. If e denotes the estimated 
propensity score, then the original sample is weighted by: 
 (i.e. treated subjects are assigned a weight equal to the reciprocal of the propensity 
score, while control subjects are assigned a weight equal to the reciprocal of one minus 
the propensity score). Since, the weights may be inaccurate or unstable for subjects 
with a very low probability of receiving the treatment received, the use of stabilizing 
weights has been proposed in literature.120 We limited the weighting thresholds such 
that weights exceeding the 1st and 99th percentile were set to that threshold. The 
estimated weights were incorporated into the logistic regression models that only 
included the anticoagulant treatment variable.  
 
Z   +   (1-Z) 
e         (1-e) 
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Sensitivity analysis: 
We conducted sensitivity analysis by restricting the use of anticoagulants in the 
first seven days after surgery to compare real world results to clinical trials where 
patients received anticoagulation within the first 7 days.  
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3.2.3 Specific Aim 3: To compare the safety of novel oral anticoagulant 
rivaroxaban with standard oral anticoagulant warfarin among patients with 
elective total hip or knee replacement surgery.  
 
Study population and study design 
For this aim, we designed a retrospective cohort study to study the effect of type 
of anticoagulant use on the safety in patients with elective total hip or knee replacement 
surgery.  All the patients identified as the members of the comparative effectiveness 
cohort for aim 2 were included in the analysis for this aim. We applied the same 
inclusion exclusion criteria as aim 2 for this cohort (Figure 3-4). Follow up period began 
from the discharge date after the orthopedic surgery and patients were followed for 90 
days after discharge.   
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Figure 3-4 Study design for Aim 3 
 
Measurement of variables 
The outcomes of interest were the occurrence of major bleeding, intracranial 
hemorrhage (ICH), gastrointestinal (GI) bleeding and peri-prosthetic infection in the 
follow‐up period. Outcomes were assessed based on the presence of inpatient or 
outpatient claims with a primary diagnosis. Validated ICD‐9 coding algorithms and 
mapped ICD 10 codes (Table 3-5) were used to measure the bleeding events and 
periprosthetic infection, which are based on published studies found in the literature.121 
Baseline covariates included in the propensity model were age, gender, year of surgery, 
census region of residence, type of health benefit plan, measure of the generosity of the 
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prescription drug benefit, CCI, previous bleeding, peptic ulcer, gastritis, duodenitis, 
esophagitis, atrial fibrillation, diabetes, dementia, hypertension, cardiovascular 
diseases, congestive heart failure, hepatic failure, renal failure, sleep apnea, anemia, 
number of hospitalizations, type of surgery setting, gastroprotective agents, antiplatelet 
therapy, ACE inhibitors and statins. The number of events were used to calculate 
bleeding and PJI rates in the two user cohorts. 
Table 3-5 Medical diagnosis codes for outcomes in aim 3 
Diagnosis ICD-9 CM and ICD-10 CM 
Major bleeding 360.43, 362.81, 372.72, 376.32, 379.23, 423.0, 430, 431, 432, 568.81, 
719.1,852, 853, 854, 363.61 
Gastrointestinal 
bleeding event  
530.82, 531.2, 531.4, 531.6, 532.2, 532.4, 
532.6, 533.2, 533.4, 533.6, 534.2, 534.4, 
534.6, 535.x1, 537.83, 562.02, 562.03, 
562.12, 562.13, 569.3, 578.x, K92.2, K29.x 
Intracranial 
bleeding event 
430.x, 431.x, 432.0, 432.1, 432.2, 432.9, 
or 851-854, I61.9, I62 
Any bleeding 360.43, 362.81, 363.61, 372.72, 376.32, 379.23, 423.0, 430, 431, 432, 
852.0, 852.2, 852.4, 853.0, 455.2, 455.5, 455.8, 456.0, 456.20, 459.0, 
530.7, 530.82, 531.00, 531.01, 531.20, 531.21, 531.40, 531.41, 531.60, 
531.61, 533.01, 533.20, 533.21, 533.40, 533.41, 533.60 , 533.61 , 
534.00 , 534.01, 534.20, 534.21 , 534.40, 534.41, 531.01, 534.60, 
534.61, 535.11, 535.21 , 535.31 , 535.41 , 535.51, 535.61, 537.83, 
562.02, 562.03 , 562.12 , 562.13, 568.81, 569.3, 569.85, 578, 578.0 , 
578.1 , 578.9 , 593.81, 599.7 , 719.10, 719.11, 719.12 , 719.13 , 719.14, 
719.15, 719.16, 719.17, 719.18, 719.19, 784.7, 784.8, 786.3, R58 
Prosthetic joint 
infection 
996.66, T84.5 
 
 Statistical analysis 
Descriptive statistics were generated including the event rates in each 
anticoagulant group and distributions of baseline characteristics. We estimated odds 
ratios (ORs) and 95% confidence intervals (CIs) using logistic regression models with 
stabilized inverse probability treatment weighting (IPTW).117  Propensity score weights 
were estimated using logistic regression. The propensity score distributions were 
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examined by exposure status for overlap to assess factors associated with overall 
treatment selection and comparability of the covariate distributions. We then estimated 
the treatment effects using propensity score weighting, including IPTW approaches, 
trimming for non‐overlapping regions. The estimated weights were incorporated into the 
logistic regression models that only included the anticoagulant treatment variable.  
Sensitivity analysis: 
Similar to aim 2, we conducted a sensitivity analysis by restricting the use of 
anticoagulants in the first seven days after surgery to compare real world results to 
clinical trials where patients received anticoagulation within the first 7 days.  
3.3 Power calculations 
Power and sample size calculations were based on previous literature. 1 The 
power calculation in RE-LY trial indicated 1,275 patients should be included in each 
study arm to demonstrate non-inferiority between dabigatran and warfarin. We will 
require the same number of subjects in each anticoagulant drug class that would be 
needed in order to have power of 80% to detect statistically significant differences 
between those exposed to standard therapy compared to those exposed to newer oral 
anticoagulants for experiencing the primary outcome. 
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Chapter 4 : RESULTS 
 
This chapter presents the three main findings of this study. In this chapter, we 
analyzed the utilization patterns of anticoagulants in real-world clinical practice and 
evaluated the factors influencing the choice of preventive anticoagulant therapy in 
patients undergoing an elective hip or knee replacement surgery using health insurance 
claims from Marketscan databases during the period of 2011 to 2015. We also 
compared the effectiveness and safety of rivaroxaban and warfarin in elective 
orthopedic surgery patients. 
 
4.1 Aim 1a Real world utilization of anticoagulants after an elective total hip or 
knee replacement 
Trends in the utilization pattern of anticoagulants after an elective total hip or 
knee replacement surgery were examined between January 1, 2010 and December 31, 
2015. This time period was chosen to reflect the effect of introduction of novel 
anticoagulants in the US market.  Dabigatran was the first non-Vitamin K oral 
anticoagulant approved by the US FDA on October 19, 2010. However, it was approved 
for stroke prevention indication in patients with atrial fibrillation. On November 23, 2015, 
dabigatran received approved for VTE prevention after hip replacement surgery. 
Rivaroxaban was the first approved novel oral anticoagulant for VTE prophylaxis after 
knee and hip replacement surgeries and received FDA approval on July 1, 2011. 
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Apixaban was introduced to the US market on December 28, 2012, but received 
approval for VTE prophylaxis indication following hip and knee replacement surgery on 
March 18, 2014. 
The number of patients having total hip replacement each quarter and the 
number of prescriptions for each anticoagulant are represented in Figure 4-1 and Figure 
4-2 for commercially insured and Medicare populations respectively. 
 
Figure 4-1 Market trend for anticoagulant utilization in commercially insured total 
hip replacement patients 
 
No pharmacological prophylaxis was defined as lack of claims on pharmacological agents in the follow up 
period; new oral anticoagulants included rivaroxaban, apixaban and dabigatran; other pharmacological 
agents included heparins, prescription aspirin, and fondaparinux 
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Figure 4-2 Market trend for anticoagulant utilization in Medicare total hip 
replacement patients 
 
No pharmacological prophylaxis was defined as lack of claims on pharmacological agents in the follow up 
period; new oral anticoagulants included rivaroxaban, apixaban and dabigatran; other pharmacological 
agents included heparins, prescription aspirin, and fondaparinux 
 
Figures 4-3 and 4-4 represent the number of patients having total knee 
replacement each quarter and the number of prescriptions for each anticoagulant in 
commercially insured and Medicare populations respectively. 
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Figure 4-3 Market trend for anticoagulant utilization in commercially insured total 
knee replacement patients 
 
No pharmacological prophylaxis was defined as lack of claims on pharmacological agents in the follow up 
period; new oral anticoagulants included rivaroxaban, apixaban and dabigatran; other pharmacological 
agents included heparins, prescription aspirin, and fondaparinux 
 
Figure 4-4 Market trend for anticoagulant utilization in Medicare total knee 
replacement patients 
 
No pharmacological prophylaxis was defined as lack of claims on pharmacological agents in the follow up 
period; new oral anticoagulants included rivaroxaban, apixaban and dabigatran; other pharmacological 
agents included heparins, prescription aspirin, and fondaparinux 
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Market share of different anticoagulants used by total hip replacement patients is 
represented in Figure 4-5 and by total knee replacement patients in Figure 4-6.  We 
segregated the utilization patterns by type of insurance, commercially insured and 
Medicare patients.   
Figure 4-5 Market share of anticoagulants in total hip replacement patients 
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Figure 4-6 Market share of anticoagulants in total knee replacement patients 
 
Until the approval of rivaroxaban, warfarin and low molecular weight heparins 
shared the majority of the market share in both, hip and knee replacement surgery 
patients. Warfarin utilization was a little higher in the Medicare population compared to 
commercially insured populations in both, hip and knee replacement surgery patients.  
With rivaroxaban gaining US FDA approval in July 1, 2011, market share for warfarin 
and LMWH dropped substantially with a simultaneous increase in the market share for 
rivaroxaban. By 2nd quarter of 2012, rivaroxaban was utilized by almost a third of 
patients on anticoagulants after hip and knee replacement surgery.  
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Dabigatran, which was approved for stroke prevention in atrial fibrillation patients 
in October, 2010, was also prescribed for an off-label VTE prevention indication in some 
patients, although its use remained less than 1%. Dabigatran received approval for VTE 
prophylaxis indication in hip replacement patients on November 23, 2015 and is 
reflected by a short spike in its use in Medicare patients in 3rd quarter of 2015. Apixaban 
is the newest addition to the non-Vitamin K oral anticoagulants and received US FDA 
approval for VTE prophylaxis after hip and knee replacement surgeries in March, 2014. 
Use of apixaban has steadily increased since 3rd quarter of 2014 which may explain 
why the proportion of warfarin users seems to further decrease in 2015. 
 
4.2 Aim 1b Predictors of choice of anticoagulant after elective total hip and knee 
replacements 
Due to the insufficient sample size of newer oral anticoagulants- dabigatran and 
apixaban in our data, we decided to only include rivaroxaban as the newer oral 
anticoagulant comparator in all the subsequent aims. 
4.2.1 Descriptive statistics 
A total of 117,393 commercially insured patients and 67,207 Medicare patients 
were identified as undergoing elective total hip replacement surgery between June 1, 
2011 and September 30, 2015. Of these, 12,876 warfarin new users and 10,892 
rivaroxaban users were included in the final commercially insured cohort (Figure 4-7) 
and 7,416 new warfarin users and 4,739 rivaroxaban new users were included in the 
final Medicare cohort (Figure 4-8).   
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Figure 4-7 Sample derivation flow chart for commercially insured elective total hip 
replacement surgery patients 
 
THR diagnosis (using ICD 9 and 10 and CPT codes) recorded on 
either inpatient or outpatient service claims between July 1, 2011 to 
September 30, 2015 (n=117,393) 
 
Exclude: Age < 18 (n=151) 
Continuous enrollment (n=34,063) 
Eligibility requirements: Patients >18 yrs with 270 days continuous 
enrollment (180 days pre-index + 90 days post-index) in their health 
plan (n=83,179) 
 
Exclude: No use of anticoagulants or use of more 
than 1 anticoagulants following surgery (n=57,534) 
 
Patients using rivaroxaban or warfarin following surgery (n=25,645) 
Exclude: Prevalent users of rivaroxaban or warfarin 
(n=1,877) 
New users of anticoagulants following surgery 
Final sample 
23,768 
(Warfarin users: 12,876 Rivaroxaban users: 10,892) 
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Figure 4-8 Sample derivation flow chart for Medicare elective total hip 
replacement surgery patients 
 
THR diagnosis (using ICD 9 and 10 and CPT codes) recorded on 
either inpatient or outpatient service claims between July 1, 2011 to 
September 30, 2015 
n=67,207 
 
Exclude: Age < 18 (n=41) 
Continuous enrollment (n=17,018) 
Eligibility requirements: Patients >18 yrs with 210 days continuous 
enrollment (180 days pre-index + 90 days post-index) in their health 
plan (n=50,148) 
 
Exclude: Patients not on warfarin or rivaroxaban or 
using multiple anticoagulants following surgery 
(n=35,913) 
Patients using rivaroxaban or warfarin following surgery (n=14,235) 
Exclude: Prevalent users of rivaroxaban or warfarin 
(n=2,080) 
New users of anticoagulants following surgery 
Final sample 
12,155 
(Warfarin users: 7,416 Rivaroxaban users: 4,739) 
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A total of 212,808 commercially insured patients and 132,073 Medicare patients 
were identified as undergoing elective total knee replacement surgery between June 1, 
2011 and September 30, 2015. Of these, 24,856 were new users of warfarin and 21,398 
were new users of rivaroxaban in the final commercially insured cohort (Figure 4-9) and 
15,483 were new users of warfarin and 8,997 were new users of rivaroxaban in the final 
Medicare cohort (Figure 4-10).   
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Figure 4-9 Sample derivation flow chart for commercially insured elective total 
knee replacement surgery patients 
 
TKR diagnosis (using ICD 9 and 10 and CPT codes) recorded on 
either inpatient or outpatient service claims between July 1, 2011 to 
September 30, 2015 
n=212,808 
 
Exclude: *42 with second surgery 
Age < 18 (n=165) 
Continuous enrollment (n=59,571) 
Eligibility requirements: Patients >18 yrs with 270 days continuous 
enrollment (180 days pre-index + 90 days post-index) in their health 
plan (n=153,072) 
 
Exclude: No use of anticoagulants or use of more 
than 1 anticoagulants following surgery 
(n=103,545) 
Patients using rivaroxaban or warfarin following surgery (n=49,527) 
Exclude: Prevalent users of rivaroxaban or warfarin 
(n=3,273) 
New users of anticoagulants following surgery 
Final sample 
46,254 
(Warfarin users: 24,856 Rivaroxaban users: 21,398) 
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Figure 4-10 Sample derivation flow chart for Medicare elective total knee 
replacement surgery patients 
 
TKR diagnosis (using ICD 9 and 10 and CPT codes) recorded on 
either inpatient or outpatient service claims between July 1, 2011 to 
September 30, 2015 
n=132,073 
 
Exclude:  
Age < 18 (n=94) 
Continuous enrollment (n=33,137) 
Eligibility requirements: Patients >18 yrs with 270 days continuous 
enrollment (180 days pre-index + 90 days post-index) in their health 
plan (n=98,842) 
 
Exclude: No use of anticoagulants or use of other 
anticoagulants following surgery (n=66,463) 
Patients using rivaroxaban or warfarin following surgery (n=28,379) 
Exclude: Prevalent users of rivaroxaban or warfarin 
(n=3,899) 
New users of anticoagulants following surgery 
Final sample 
24,480 
(Warfarin users: 15,483 Rivaroxaban users: 8,997) 
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4.2.2 Baseline characteristics 
Patient sociodemographic characteristics among new users of warfarin and 
rivaroxaban after an elective hip replacement surgery are shown in table 4-1, including 
the absolute standardized differences for comparing baseline characteristics between 
the two groups of anticoagulant users. Comparison of the baseline variables suggested 
that new users of rivaroxaban after total hip replacement were more likely to live in the 
southern region (43.08% vs 32.15%, absolute standardized difference 0.29 in the 
commercial population and 32.39% vs 23.49%, absolute standardized difference 0.23 in 
the Medicare population) and were more likely to have surgeries in the later years 
(30.25% vs 24.55% in 2013, 24.65% vs 15.9% in 2014 and 9.43% vs 5.5% in 2015, 
standardized difference 0.50 in commercially insured population and 29.54% vs 25.05% 
in 2013, 26.23% vs 14.74% in 2014 and 11.67% vs 5.77% in 2015, standardized 
difference 0.58 in Medicare population).    
Table 4-1 Baseline characteristics of patients with elective total hip replacement 
surgery 
 Commercially insured Medicare insured 
Baseline 
Characteristic 
Warfarin  
N=12,876 
N (%) 
Rivaroxaban 
N=10,892 
N (%) 
Standardized 
difference┼ 
Warfarin 
N=7,416 
N (%) 
Rivaroxaban 
N=4,739  
N (%) 
Standardized 
difference┼ 
Predisposing Characteristics 
    
Patient Age  
(Mean (SD)) 
 
55.98 (6.92) 
 
56.04 (6.81) 
 
0.01 74.27 (6.54) 73.70 (6.44) -0.09 
Female 
 
6,568 
(51.01) 
 
5,380 
(49.39) 
-0.02 4,4452 
(60.03) 2,766 (58.37) -0.09 
 
Region 
  Northeast 
 
 
2,742 (21.3) 
 
 
1,357 (12.46) 
 
 
0.29 
1,861 
(25.09) 866 (18.27) 0.23 
  North Central 
3,737 
(29.02) 
2,942 (27.01)  
2,557 
(34.48) 1,618 (34.14)  
  South 
4,139 
(32.15) 
4,692 (43.08)  
1,742 
(23.49) 1,535 (32.39)  
  West 2,176 (16.9) 1,862 (17.10)  
1,229 
(16.57) 706 (14.9)  
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  Unknown 82 (0.64) 39 (0.36)  27 (0.36) 14 (.3)  
MSA 
10,992 
(85.37) 
9,251 (84.93) -0.01 
6,204 
(83.66) 4,073 (85.95) 0.06 
Time of Surgery   0.50   0.58 
   2011 
2,707 
(21.02) 
684 (6.28)  
1,499 
(20.21) 231 (4.87)  
   2012 
4,246 
(32.98) 
3,201 (29.39)  
2,538 
(34.22) 1,312 (27.69)  
   2013 
3,161 
(24.55) 
3,295 (30.25)  
1,858 
(25.05) 1,400 (29.54)  
   2014 2,047 (15.9) 2,685 (24.65)  
1,093 
(14.74) 1,243 (26.23)  
   2015 715 (5.5) 1,027 (9.43)  428 (5.77) 553 (11.67)  
 
Enabling Resources 
 
   
  0.10 
Insurance plan   0.13    
  Basic Medical 458 (3.56) 311 (2.86)  93 (1.25) 47 (0.99)  
  Comprehensive 
490 (3.81) 414 (3.80) 
 
 
2,657 
(35.83) 1,733 (36.57)  
 EPO 133 (1.03) 98 (0.90)  13 (0.18) 13 (0.27)  
HMO 
1,408 
(10.94) 
925 (8.49)  
888 (11.97) 437 (9.22)  
  POS 937 (7.28) 671 (6.16)  249 (3.36) 193 (4.07)  
  PPO 
8,031 
(62.37) 7,135 (65.51) 
 
3,449 
(46.51) 2,273 (47.96)  
POS with capitation 93 (0.72) 35 (0.32)  18 (0.24) 9 (0.19)  
  CDHP 866 (6.73) 849 (7.79)  40 (0.54) 27 (0.57)  
HDHP 460 (3.57) 454 (4.17)  9 (0.12) 7 (0.15)  
Prescription benefits 
generosity 
  No/poor coverage (> 
0.80 and ≤ 1) 
1,633 
(12.68) 1,359 (12.48) 
0.05 
 
494 (6.66) 323 (6.82) 0.12 
  Fair coverage (> 
0.20 and ≤ 0.80) 
6,928 
(53.81) 5,661 (51.97) 
 
4,936 
(66.56) 2,900 (61.19)  
  Good coverage (≥ 0 
and ≤ 0.20) 3,35 (26.06) 3,073 (21.28) 
 
1,815 
(24.47) 1,381 (29.14)  
Unknown 960 (7.46) 799 (7.34)  171 (2.31) 135 (2.85)  
Need 
characteristics   
 
   
DVT 104 (0.81) 63 (0.58) -0.03 117 (1.58) 40 (0.84) -0.07 
PE 104 (0.81) 61 (0.56) -0.03 139 (1.87) 61 (1.29) -.0.05 
DVT and PE 39 (0.30) 20 (0.18) -0.02 51 (0.69) 16 (0.34) -0.05 
Ischemic Stroke 164 (1.27) 142 (1.30) 0.00 423 (5.70) 282 (5.95) 0.01 
Myocardial Infarction 114 (0.89) 94 (0.86) 0.00 150 (2.02) 97 (2.05) 0.00 
Major Bleeding 482 (3.74) 434 (3.98) 0.01 447 (6.03) 274 (5.78) -0.01 
Charlson Comorbidity 
Index (CCI)   
0.03 
  0.02 
   0 
10,309 
(80.06) 8,796 (80.76) 
 
4,775 
(64.39) 3,104 (65.50)  
   1 
1,419 
(11.02) 1,198 (11.0) 
 
1,235 
(16.65) 772 (16.29)  
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   2-4 
1,040 (8.08) 832 (7.64) 
 
1,293 
(17.44) 794 (16.75)  
   ≥5 108 (0.84) 66 (0.61)  113 (1.52) 69 (1.46)  
Atrial fibrillation 241 (1.87) 157 (1.44) -0.03 515 (6.94) 230 (4.85) -0.09 
Cardiovascular 
Diseases 1,002 (7.78) 870 (7.99) 
0.01 
1,875 
(25.28) 1,132 (23.89) -0.03 
Congestive Heart 
Failure 188 (1.46) 158 (1.45) 
0.00 
357 (4.81) 188 (3.97) -0.04 
Hepatic Failure 267 (2.07) 242 (2.22) 0.01 129 (1.74) 86 (1.81) 0.01 
Renal Impairment 288 (2.24) 185 (1.7) -0.04 479 (6.46) 246 (5.19) 0.05 
Peptic Ulcer 20 (0.16) 14 (0.13) -0.01 24 (0.32) 9 (0.19) -0.03 
Gastritis 87 (0.68) 87 (0.80) 0.01 84 (1.13) 61 (1.29) 0.01 
Duodeniitis 21 (0.16) 22 (0.2) 0.01 19 (0.26) 15 (0.32) 0.01 
Esophagitis 43 (0.33) 50 (0.46) 0.02 37 (0.50) 29 (0.61) 0.02 
Hyperlipidemia 
2,891 
(22.45) 2,544 (23.36) 
0.02 
2,247 (30.3) 1,525 (32.18) 0.04 
Hypertension 
5,434 (42.2) 4,843 (44.46) 
0.05 
4,637 
(62.53) 2,983 (62.95) 0.01 
Diabetes Mellitus 
1,528 
(11.87) 1,257 (11.54) 
-0.01 
1,379 
(18.59) 828 (17.47) -0.03 
Anemia 1,013 (7.87) 858 (7.88) 0.00 787 (10.61) 480 (10.13) -0.02 
Sleep Apnea 864 (6.71) 736 (6.76) 0.00 457 (6.16) 299 (6.31) -0.01 
Cancer 578 (4.49) 442 (4.06) -0.02 783 (10.56) 502 (10.59) 0.00 
Dementia 3 (0.02) 1 (0.01) -0.01 17 (0.23) 15 (0.32) 0.02 
Obesity 1,066 (8.28) 887 (8.14) 0.00 382 (5.15) 267 (5.63) 0.02 
Number of 
hospitalizations 460 (3.57) 380 (3.49) 
0.00 
458 (6.18) 285 (6.01) -0.01 
Outpatient Surgery 
Setting 251 (1.95) 205 (1.88) 
0.00 
306 (4.13) 190 (4.01 0.01 
Antiplatelet Therapy 266 (2.07) 179 (1.64) -0.03 453 (6.11) 285 (6.01) 0.00 
Gastroprotective 
Agents 
2,598 
(20.18) 2,114 (19.41) 
-0.02 
2,013 
(27.14) 1,220 (25.74) -0.03 
Antiarrhythmics  86 (0.67) 61 (0.56) -0.01 159 (2.14) 98 (2.07) -0.01 
Rate Control Therapy 
3,447 
(26.77) 2,769 (25.42) 
-0.03 
3,670 
(49.49) 2,119 (46.40) -0.06 
Hormone Use 153 (1.19) 117 (1.07) -0.01 2 (0.03) 0 (0.00) -0.02 
Statins  
3,679 
(28.57) 3,005 (27.59) 
-0.02 
3,588 
(48.38) 2,214 (46.72) -0.03 
ACE Inhibitors  
4,467 
(34.69) 3,868 (35.51) 
0.02 
3,679 
(49.61) 2,320 (48.96) -0.01 
       
┼Standardized difference is the difference in means or proportions divided by standard error; imbalance is 
defined as absolute value greater than 0.20112 (≥0.2 - <0.5: small effect size; ≥0.5 - <0.8: medium effect 
size; and ≥0.8: large effect size) 
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Table 4-2 shows patient sociodemographic characteristics among new users of 
warfarin and rivaroxaban after an elective knee replacement surgery, including the 
absolute standardized differences for each characteristic category between the two 
anticoagulants. Comparison of the baseline variables suggested that new users of 
rivaroxaban after total knee replacement were more likely to live in the southern region 
(48.54% vs 34.23%, absolute standardized difference 0.37 in the commercial population 
and 40.19% vs 26.08%, absolute standardized difference 0.36 in the Medicare 
population) and were more likely to have surgeries in the later years (28.61% vs 23.91% 
in 2013, 25.16% vs 16.54% in 2014 and 10.01% vs 6.02% in 2015, standardized 
difference 0.47 in commercially insured population and 30.50% vs 25.56% in 2013, 
25.29% vs 14.68% in 2014 and 10.16% vs 5.25% in 2015, standardized difference 0.55 
in Medicare population).    
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Table 4-2 Baseline characteristics of patients with elective total knee replacement 
surgery 
 Commercially insured Medicare insured 
Baseline 
Characteristic 
Warfarin 
N=24,856  
N (%) 
Rivaroxaban 
N=21,398 
N (%) 
Standardized 
difference┼ 
Warfarin 
N=15,483 
N (%) 
Rivaroxaban 
N=8,997  
N (%) 
Standardized 
difference┼ 
Predisposing Characteristics 
    
Patient Age  
(Mean (SD)) 57.73 (5.28) 57.35 (5.52) -0.07 73.45 (5.99) 72.70 (5.78) -0.13 
Female 
15,206 
(61.18) 
12,888 
(60.23) 
-0.07 
9,536 
(61.59) 5,310 (59.02) -0.13 
 
Region 
  Northeast 
4,963 
(19.97) 
1,995 (9.32) 0.37 3,645 
(23.54) 1,169 (12.99) 0.36 
  North Central 
7,645 
(30.76) 
5,702 (26.65)  
5,554 
(35.87) 3,000 (33.34)  
  South 
8,507 
(34.23) 
10,386 
(48.54) 
 
4,038 
(26.08) 3,616 (40.19)  
  West 
3,563 
(14.33) 
3,230 (15.09)  
2,201 
(14.22) 1,187 (13.19)  
  Unknown 178 (0.72) 85 (0.4)  45 (0.29) 25 (0.28)  
MSA 
20,618 
(82.95) 
17,443 
(81.52) 
-0.04 
13,026 
(84.13) 7,500 (83.36) -0.02 
Time of Surgery   0.47   0.55 
   2011 
5,327 
(21.43) 
1,497 (7.00)  
3,183 
(20.56) 503 (5.59)  
   2012 
7,981 
(32.11) 
6,254 (29.23)  
5,527 
(33.95) 2,561 (28.47)  
   2013 
5,942 
(23.91) 
6,121 (28.61)  
3,957 
(25.56) 2,744 (30.50)  
   2014 
4,110 
(16.54) 
5,384 (25.16)  
2,273 
(14.68) 2,275 (25.29)  
   2015 1,496 (6.02) 2,142 (10.01)  813 (5.25) 914 (10.16)  
 
Enabling Resources 
 
   
   
Insurance plan   0.11   0.13 
  Basic Medical 980 (3.94) 636 (2.97)  199 (1.29) 96 (1.07)  
  Comprehensive 
1,152 (4.63) 946 (4.42) 
 
5,868 
(37.90) 3,689 (41.00)  
 EPO 239 (0.96) 182 (0.85)  19 (0.12) 16 (0.18)  
HMO 
2,542 
(10.23) 
1,677 (7.84)  
1,652 
(10.67) 659 (7.32)  
  POS 1,797 (7.23) 1,475 (6.89)  610 (3.94) 409 (4.55)  
  PPO 
15,663 
(52.76) 
14,026 
(47.24) 
 
7,033 
(45.42) 4,042 (44.93)  
POS with capitation 151 (0.61) 79 (0.37)  29 (0.19) 14 (0.16)  
  CDHP 1,592 (6.40) 1,631 (7.62)  59 (0.38) 60 (0.67)  
HDHP 740 (2.98) 746 (3.49)  14 (0.09) 12 (0.13)  
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Prescription benefits 
generosity 
  No/poor coverage (> 
0.80 and ≤ 1) 
2,701 
(10.87) 2,385 (11.15) 
0.06 
1,040 (6.72) 603 (6.70) 0.12 
  Fair coverage (> 
0.20 and ≤ 0.80) 
14,274 
(57.43) 
11,757 
(54.94) 
 
10,239 
(66.13) 5,480 (60.91)  
  Good coverage (≥ 0 
and ≤ 0.20) 
6,457 
(25.98) 6,114 (28.57) 
 
3,802 
(24.56) 2,679 (25.68)  
Unknown 1,424 (5.73) 1,142 (5.34)  402 (2.60) 235 (2.61)  
Need 
characteristics   
 
   
DVT 249 (1.00) 137 (0.64) -0.04 258 (1.67) 68 (0.76) -0.08 
PE 315 (1.27) 143 (0.67) -0.06 244 (1.58) 94 (1.04) -0.05 
DVT and PE 88 (0.35) 36 (0.17) -0.04 78 (0.50) 17 (0.19) -0.05 
Ischemic Stroke 344 (1.38) 298 (1.39) 0.00 786 (5.08) 445 (4.95) -0.01 
Myocardial Infarction 189 (0.76)  155 (0.72) 0.00 283 (1.83) 149 (1.66) -0.01 
Major Bleeding 1,107 (4.45) 940 (4.39) 0.00 855 (5.52) 463 (5.15) -0.02 
Charlson Comorbidity 
Index (CCI)   
0.03 
  0.05 
   0 
19,364 
(77.90) 
16,932 
(79.13) 
 
10,236 
(66.11) 6,120 (68.02)  
   1 
3,289 
(13.23) 2,700 (12.62) 
 
2,535 
(16.37) 1,472 (16.36)  
   2-4 
2,104 (8.46) 1,688 (7.89) 
 
2,586 
(16.70) 1,341 (14.90)  
   ≥5 99 (0.40) 78 (0.36)  126 (0.81) 64 (0.71)  
Atrial fibrillation 476 (1.92) 356 (1.66) -0.02 927 (5.99) 380 (4.22) -0.08 
Cardiovascular 
Diseases 2,257 (9.08) 1,857 (8.68) 
-0.01 
3,845 
(24.83) 2,006 (22.30) -0.06 
Congestive Heart 
Failure 372 (1.50) 288 (1.35) 
-0.01 
650 (4.20) 272 (3.02) -0.06 
Hepatic Failure 609 (2.45) 520 (2.43) 0.00 263 (1.70) 153 (1.17) 0.00 
Renal Impairment 539 (2.17) 381 (1.78) -0.03 863 (5.57) 425 (4.72) -0.04 
Peptic Ulcer 27 (0.11) 22 (0.10) 0.00 21 (0.14) 22 (0.24) 0.03 
Gastritis 236 (0.95) 218 (1.02) 0.01 171 (1.10) 107 (1.19) 0.01 
Duodeniitis 32 (0.13) 29 (0.14) 0.00 25 (0.16) 14 (0.16) 0.00 
Esophagitis 144 (0.58) 99 (0.46) -0.02 106 (0.68) 56 (0.62) -0.01 
Hyperlipidemia 
6,437 
(25.90) 5,516 (25.78) 
0.00 
4,761 
(30.75) 2,736 (30.41) -0.01 
Hypertension 
12,556 
(50.51) 
11,202 
(52.35) 
0.04 
10,092 
(65.18) 5,845 (64.97) 0.00 
Diabetes Mellitus 
4,544 
(18.28) 3,797 (17.74) 
-0.01 
3,540 
(22.86) 2,051 (22.80) 0.00 
Anemia 2,053 (8.26) 1,699 (7.94) -0.01 1,515 (9.78) 816 (9.07) -0.02 
Sleep Apnea 
2,529 
(10.17) 2,212 (10.34) 
0.01 
1,217 (7.86) 743 (8.25) 0.02 
Cancer 1,021 (4.11) 801 (3.74) -0.01 1,480 (9.56) 822 (9.14) -0.01 
Dementia 5 (0.02) 5 (0.02) 0.00 29 (0.19) 7 (0.08) -0.03 
Obesity 
2,918 
(11.74) 2,499 (11.68) 
0.00 
1,039 (6.71) 637 (7.08) 0.01 
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Number of 
hospitalizations 763 (3.07) 646 (3.02) 
0.00 
697 (4.50) 335 (3.72) -0.04 
Outpatient Surgery 
Setting 518 (2.08) 389 (1.82) 
0.02 
587 (3.79) 348 (1.87) 0.00 
Antiplatelet Therapy 583 (2.35) 404 (1.89) -0.03 946 (6.11) 506 (5.62) 0.02 
Gastroprotective 
Agents 
6,376 
(25.65) 5,451 (25.47) 
0.00 
4,678 
(30.21) 2,687 (29.87) -0.01 
Antiarrhythmics  205 (0.82) 154 (0.72) -0.01 351 (2.27) 167 (1.86) -0.03 
Rate Control Therapy 
7,924 
(31.88) 6,637 (31.02) 
-0.01 
7,993 
(51.62) 4,502 (50.04) -0.03 
Hormone Use 143 (0.58) 145 (0.68) 0.01 2 (0.01) 0 (0.00) -0.02 
Statins  
8,473 
(32.09) 7,089 (31.13) 
-0.02 
7,890 
(50.96) 4,558 (50.66) -0.01 
ACE Inhibitors  
10,544 
(42.42) 9,281 (43.37) 
0.02 
8,307 
(53.65) 4,839 (53.78) 0.00 
       
┼Standardized difference is the difference in means or proportions divided by standard error; imbalance is 
defined as absolute value greater than 0.20 (small effect size) 
 
4.2.3 Multivariate analyses of anticoagulant selection 
The results of our multivariate model that evaluated the influence of various 
baseline characteristics on the choice of anticoagulant treatment in total hip 
replacement patients are presented in table 4-3. Warfarin was used as the referent 
group for all analyses. In the commercial cohort, sex, geographic region and time of 
surgery were found to be significant predisposing predictors of choice of anticoagulant 
therapy. Females had lower odds of being prescribed rivaroxaban than males (OR 0.92, 
95% CI 0.87-0.97). Patients in the western region had significantly higher odds of 
rivaroxaban prescription compared to patients in northeast (OR 2.34, 95% CI 2.16-
2.54). Patients having surgery in 2015 had higher odds of being prescribed rivaroxaban 
than ones having a surgery in 2011 (OR 5.86, 95% CI 5.14-6.67). In the Medicare 
cohort, age, geographic region and time of surgery were found to be significant 
predisposing predictors.  Each year increase in age reduced the odds of rivaroxaban 
initiation by 1.3% (OR 0.99, 95% CI 0.98-0.99). Patients in the western region had 
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significantly higher odds of rivaroxaban prescription compared to patients in northeast 
(OR 1.95, 95% CI 1.74-2.18). Patients having surgery in 2015 had higher odds of being 
prescribed rivaroxaban than ones having a surgery in 2011 (OR 9.09, 95% CI 7.50-
11.02). 
 In the commercial cohort, type of health plan was found to a significant enabling 
variable in the choice of anticoagulant, with patients with point of service with capitation 
plan having the lowest odds of rivaroxaban initiation (OR 0.40, 95% CI 0.26-0.62). 
Comorbidities such as cardiovascular diseases, renal impairment, and hypertension 
also significantly affected the odds of rivaroxaban initiation in these patients. Patients 
with a history of cardiovascular diseases had higher odds of being prescribed 
rivaroxaban than those without (OR 1.14, 95% CI 1.01-1.28) and those with renal 
impairment had lower odds of rivaroxaban prescription (OR 0.71, 95% CI 0.58-0.87). 
Patients with hypertension also had higher odds of being initiated on rivaroxaban (OR 
1.13, 95% CI1.05-1.21). 
In the Medicare population, patients with previous deep vein thrombosis (OR 
0.51, 95% CI 0.31-0.83) or pulmonary embolism (OR 0.66, 95% CI 0.45-0.97) or atrial 
fibrillation (OR 0.65, 95% CI 0.54-0.78) had lower odds of being prescribed rivaroxaban. 
Patients with renal impairment also had lower odds of rivaroxaban initiation than ones 
without (OR 0.78, 95% CI 0.64-0.94). Compared to no history of use in the pre-index 
period, use of antiplatelet agents and rate control agents decreased the odds of 
rivaroxaban initiation in the commercial cohort by 26% (OR 0.74, 95% CI 0.60-0.92) and 
9% (OR 0.91, 95% CI 0.85-0.97) respectively.  
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Table 4-3 Odds of receiving rivaroxaban versus warfarin in total hip replacement 
patients 
Patient Characteristics Commercially insured 
OR (95% CI) 
Medicare 
OR (95% CI) 
Predisposing Characteristics  
Age at the time of surgery 1.00 (1.00-1.00) 0.99* (0.98-0.99) 
Sex 
        Male 
        Female 
 
1 
0.92* (0.87-0.97) 
 
1 
0.94 (0.87-1.02) 
Geographic Region 
       Northeast 
       North central 
       West 
       South  
 
1 
1.64* (1.50 -1.79) 
2.34* (2.16-2.54) 
1.81* (1.64 -1.99) 
 
 
1 
1.30* (1.17-1.45) 
1.95* (1.74-2.18) 
1.38* (1.21-1.58) 
Metropolitan Statistical Area 
       MSA 
       Non MSA 
  
1.02 (0.94-1.10) 
1 
 
1.21* (1.09-1.35) 
1 
Time of surgery 
       2011 
       2012 
       2013 
       2014 
       2015 
 
1 
3.01* (2.74-3.32) 
4.25* (3.85-4.69) 
5.37* (4.84-5.95) 
5.86* (5.14-6.67) 
 
1 
3.47* (2.97-4.05) 
5.07* (4.34-5.94) 
7.78* (6.60-9.18) 
9.09* (7.50-11.02) 
Enabling Resources   
Type of health benefit plan 
       Basic Medical 
       Comprehensive 
       EPO 
       HMO 
       POS 
       PPO 
       POS with capitation 
       CDHP 
       HDHP 
 
 
 
1 
0.77* (0.62-0.95) 
0.77 (0.56-1.06) 
0.59* (0.49-0.71) 
0.67* (0.55-0.80) 
0.78* (0.66-0.92) 
0.40* (0.26-0.62) 
0.73* (0.61-0.89) 
         0.80* (0.65-0.99) 
 
1 
1.00 (0.87-1.47) 
1.36 (0.55-3.35) 
0.84 (0.57-1.24) 
1.03 (0.68-1.57) 
1.01 (0.67-1.47) 
0.66 (0.27-1.64) 
0.68 (0.36-1.26) 
0.61 (0.21-1.81) 
 
Prescription benefits generosity 
       No/poor coverage  
       Fair coverage  
       Good coverage  
 
1 
1.00 (0.92-1.08) 
 0.97 (0.88 -1.06) 
 
 
1 
0.90 (0.70-1.05) 
0.94 (0.79-1.11) 
 
 
Need Characteristics   
Past clinical events   
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Previous VTE events 
        DVT  
        PE 
        DVT and PE  
 
0.70 (0.47-1.04) 
0.72 (0.48-1.09) 
1.12 (0.50-2.49) 
 
0.51* (0.31-0.83) 
0.66* (0.45-0.97) 
1.35 (0.58-3.15) 
Previous ischemic stroke 1.14 (0.89-1.45) 1.10 (0.93-1.30) 
Previous myocardial infarction 0.96 (0.71-1.30) 1.04 (0.78-1.38) 
Previous major bleeding 1.07 (0.93 -1.23) 0.98 (0.82-1.15) 
Comorbidities   
Charlson Comorbidity Index 
(CCI) 
    0 
    1 
    2-4 
    ≥5 
 
 
1 
1.03 (0.94-1.12) 
0.85 (0.70-1.02) 
0.64* (0.44-0.95) 
 
 
1 
1.01 (0.90-1.13) 
1.05 (0.84-1.31) 
1.09 (0.70-1.69) 
Atrial Fibrillation 0.82 (0.65-1.04) 0.65* (0.54-0.78) 
Cardiovascular Diseases 1.14 (1.01-1.28) 0.99 (0.89-1.09) 
Congestive Heart Failure 1.25 (0.95-1.66) 0.87 (0.67-1.13) 
Hepatic failure 1.21 (0.96-1.51) 1.02 (0.74-1.42) 
Renal Impairment 0.71* (0.58-0.87) 0.78* (0.64-0.94) 
Peptic Ulcer 0.85 (0.42-1.76) 0.55 (0.24-1.23) 
Gastritis 1.15 (0.83-1.59) 1.20 (0.83-1.71) 
Duodeniitis 1.23 (0.64-2.36) 0.97 (0.47-2.01) 
Esophagitis 1.50 (0.97-2.33) 1.27 (0.75-2.15) 
Hyperlipidemia 1.04 (0.97-1.12) 1.02 (0.93-1.11) 
Hypertension 1.13* (1.05-1.21) 1.07 (0.98-1.17) 
Diabetes Mellitus 0.98 (0.90-1.07) 0.92 (0.83-1.03) 
Anemia 1.01 (0.91-1.12) 0.94 (0.82-1.17) 
Sleep Apnea 0.97 (0.87-1.08) 0.98 (0.84-1.16) 
Cancer 1.12 (0.90-1.41) 0.96 (0.76-1.22) 
Dementia 0.28 (0.03-2.77) 1.55 (0.73-3.29) 
Obesity 0.91 (0.83-1.01) 0.94 (0.79-1.12) 
Previous Hospitalization 
      No hospitalization 
      At least 1 hospitalization 
 
 
1 
1.11 (0.95-1.29) 
 
1 
1.15 (0.97-1.37) 
Outpatient Surgery Setting 
      Inpatient 
      Outpatient 
 
1 
0.91 (0.75-1.10) 
 
1 
1.07 (0.87-1.30) 
Concomitant therapy   
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 Antiplatelet Therapy 0.74* (0.60-0.92) 1.08 (0.91-1.28) 
 Gastroprotective Agents 0.95 (0.88-1.02) 0.94 (0.86-1.03) 
 Antiarrhythmics  0.97 (0.67-1.40) 1.29 (0.97-1.72) 
 Rate Control Therapy 0.91* (0.85-0.97) 0.96 (0.88-1.04) 
 Hormone Use 0.92 (0.71-1.19) - 
 Statins  0.94 (0.88-1.01) 0.95 (0.87-1.03) 
 ACE Inhibitors  0.97 (0.90-1.04) 0.99 (0.91-1.08) 
* denotes a significant statistical difference 
 
 
Table 4-4 presents the results of our logistic regression model that evaluated the 
influence of various predictors on the type of anticoagulant initiated after a total knee 
replacement. The predisposing variables patient age at the time of surgery, sex, 
geographic region, and year of surgery were found to be significant predictors of type of 
anticoagulant initiated. Each year increase in age reduced the odds of rivaroxaban 
initiation by 1.6% in the commercial cohort (OR 0.98, 95% CI 0.98-0.99) and by 2.6% in 
the Medicare cohort (OR 0.98, 95% CI 0.97-0.98). Females were less likely to be 
initiated on rivaroxaban compared to males (OR 0.94, 95% CI 0.90-0.93 in the 
commercial cohort and OR 0.89, 95% CI 0.84-0.94 in the Medicare cohort). Patients in 
the western region had significantly higher likelihood of rivaroxaban prescription 
compared to patients in northeast (OR 3.16, 95% CI 2.97-3.37 in the commercial cohort 
and OR 2.88, 95% CI 2.65-3.13 in the Medicare cohort). Patients having surgery in 
2015 were more likely to be prescribed rivaroxaban than ones having a surgery in 2011 
(OR 5.48, 95% CI 5.01-5.99 in commercially insured patients and OR 7.83, 95% CI 
6.82-8.99 in Medicare patients).  In the commercial cohort, type of health plan was 
found to a significant enabling variable in the choice of anticoagulant, with patients with 
point of service with capitation plan having the lowest likelihood of rivaroxaban initiation 
(OR 0.52, 95% CI 0.38-0.71). 
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 Several of the need variables were found to be associated with the choice of 
anticoagulant. Compared to no previous history of deep vein thrombosis in the pre-
index period, deep vein thrombosis decreased the odds of rivaroxaban initiation by 29% 
in the commercial cohort (OR 0.71, 95% CI 0.55-0.92) and 49% in the Medicare cohort 
(OR 0.51, 95% CI 0.37-0.70). Also, patients with pulmonary embolism in the commercial 
cohort had lower odds of rivaroxaban initiation (OR 0.53, 95% CI 0.42-0.67). In the 
Medicare cohort, patients with atrial fibrillation or cardiovascular disease or 
hyperlipidemia had lower odds of rivaroxaban initiation than those without (OR 0.72, 
95% CI 0.63-0.83, OR 0.92, 95% CI 0.85-0.99, and OR 0.94, 95% CI 0.88-0.99 
respectively). Also, patients with renal impairment in both the cohorts had a lower 
likelihood of rivaroxaban initiation (OR 0.79, 95% CI 0.68-0.92 in the commercial cohort 
and OR 0.85, 95% CI 0.74-0.98 in the Medicare cohort). In the commercial cohort, 
patients that had the knee replacement surgery performed in an outpatient setting had 
16% lower odds (OR 0.84, 95% CI 0.73-0.97) of rivaroxaban initiation than those who 
had an inpatient surgery. Also, compared to no use of antiplatelet agents in the pre-
index period, use of antiplatelet agents decreased the odds of rivaroxaban initiation by 
17% (OR 0.83, 95% CI 0.72-0.96). 
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Table 4-4 Odds of receiving rivaroxaban versus warfarin in total knee replacement 
patients 
Patient Characteristics Commercially insured 
OR (95% CI) 
Medicare 
OR (95% CI) 
Predisposing Characteristics             
Age at the time of surgery 0.98* (0.98-0.99) 0.98* (0.97-0.98) 
Sex 
        Male 
        Female 
 
1 
0.94* (0.90-0.93) 
 
1 
0.89* (0.84-0.94) 
Geographic Region 
       Northeast 
       North central 
       West 
       South  
 
1 
1.95* (1.83-2.09) 
3.16* (2.97-3.37) 
2.43* (2.26-2.62) 
 
1 
1.63* (1.50-1.78) 
2.88* (2.65-3.13) 
1.93* (1.74-2.14) 
Metropolitan Statistical Area 
       MSA 
       Non MSA 
 
0.95 (0.91-1.00) 
1 
 
0.98 (0.91-1.06) 
1 
Time of surgery 
       2011 
       2012 
       2013 
       2014 
       2015 
 
1 
2.89* (2.70-3.09) 
3.79* (3.54-4.06) 
4.91* (4.57-5.28) 
5.48* (5.01-6.00) 
 
1 
3.17* (2.85-3.53) 
4.61* (4.14-5.14) 
6.95* (6.20-7.80) 
7.83* (6.82-8.99) 
Enabling Resources   
Type of health benefit plan 
       Basic Medical 
       Comprehensive 
       EPO 
       HMO 
       POS 
       PPO 
       POS with capitation 
       CDHP 
       HDHP 
 
 
 
1 
0.71* (0.61-0.82) 
0.69* (0.55-0.87) 
0.54* (0.48-0.62) 
0.70* (0.61-0.79) 
0.70* (0.63-0.79) 
0.52* (0.38-0.71) 
0.69* (0.60-0.79) 
0.74* (0.63-0.86) 
 
 
 
1 
1.07 (0.83-1.39) 
1.35 (0.63-2.88) 
0.78 (0.59-1.03) 
0.95 (0.71-1.27) 
0.98 (0.76-1.28) 
0.66 (0.32-1.35) 
1.17 (0.75-1.85) 
0.86 (0.37-2.01) 
Prescription benefits generosity 
       No/poor coverage  
       Fair coverage  
       Good coverage  
 
1 
0.96 (0.90-1.02) 
0.96 (0.90-1.03) 
 
1 
0.88* (0.79-0.99) 
0.93 (0.83-1.05) 
Need Characteristics   
Past clinical events   
Previous VTE events 
        DVT  
        PE 
        DVT and PE  
 
0.71* (0.55-0.92) 
0.53* (0.42-0.67) 
1.23 (0.72-2.12) 
 
0.51* (0.37-0.70) 
0.81 (0.61-1.08) 
0.94 (0.47-1.90) 
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Previous ischemic stroke 1.10 (0.93-1.30) 1.11 (0.98-1.27) 
Previous myocardial infarction 0.98 (0.77-1.24) 1.01 (0.81-1.26) 
Previous major bleeding 1.02 (0.93-1.12) 0.98 (0.87-1.11) 
Comorbidities   
Charlson Comorbidity Index 
(CCI) 
    0 
    1 
    2-4 
    ≥5 
 
 
1 
0.95 (0.90-1.01) 
1.00 (0.87-1.14) 
0.98 (0.68-1.40) 
 
 
1 
1.01 (0.94-1.10) 
0.95 (0.81-1.12) 
0.92 (0.62-1.38) 
Atrial Fibrillation 0.92 (0.78-1.08) 0.72* (0.63-0.83) 
Cardiovascular Diseases 1.08* (1.00 – 1.17) 0.92* (0.85-0.99) 
Congestive Heart Failure 0.94 (0.77-1.16) 0.84 (0.68-1.03) 
Hepatic failure 1.02 (0.87-1.19) 0.98 (0.77-1.24) 
Renal Impairment 0.79* (0.68-0.92) 0.85* (0.74-0.98) 
Peptic Ulcer 0.89 (0.49-1.62) 1.88 (0.97-3.62) 
Gastritis 1.08 (0.88-1.31) 1.14 (0.87-1.49) 
Duodeniitis 1.21 (0.70-2.06) 0.94 (0.46-1.92) 
Esophagitis 0.93 (0.71-1.23) 0.94 (0.66-1.33) 
Hyperlipidemia 1.01 (0.96-1.06) 0.94* (0.88-1.00) 
Hypertension 1.10* (1.05-1.15) 1.01 (0.94-1.08) 
Diabetes Mellitus 0.97 (0.92-1.02) 0.99 (0.93-1.07) 
Anemia 0.96 (0.89-1.03) 0.97 (0.88-1.07) 
Sleep Apnea 0.96 (0.90-1.03) 0.93 (0.84-1.04) 
Cancer 0.96 (0.81-1.13) 1.06 (0.88-1.26) 
Dementia 1.29 (0.33-4.99) 0.63 (0.27-1.52) 
Obesity 0.93* (0.87-0.99) 1.01 (0.90-1.13) 
Previous Hospitalization 
      No hospitalization 
      At least 1 hospitalization 
 
 
1 
1.14* (1.01-1.28) 
 
1 
0.96 (0.83-1.12) 
Outpatient Surgery Setting 
      Inpatient 
      Outpatient 
 
1 
0.84* (0.73-0.97) 
 
1 
1.15 (0.99-1.34) 
Concomittant therapy   
 Antiplatelet Therapy 0.83 (0.72-0.96) 0.99 (0.88-1.13) 
 Gastroprotective Agents 1.01 (0.96-1.06) 0.97 (0.91-1.03) 
 Antiarrhythmics  0.92 (0.72-1.17) 1.01 (0.82-1.24) 
 Rate Control Therapy 0.96 (0.92-1.00) 1.02 (0.96-1.08) 
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 Hormone Use 1.05 (0.82-1.35) - 
 Statins  0.98 (0.93-1.02) 1.03 (0.97-1.09) 
 ACE Inhibitors  1.01 (0.97-1.06) 0.99 (0.94-1.06) 
* denotes a statistically significant difference 
 
We also performed a sensitivity analysis using the purposeful selection method 
by Bursac et al to understand the effect of variable selection on the model fit.113 In this 
analysis, variables were included in the model only if they had univariate associations at 
the significance level of 0.25 or higher with the outcome. In the iterative process of 
variable selection, covariates were removed from the model if they were non-significant 
(significance was evaluated at the 0.1 alpha level) and not a confounder (confounding 
was defined as a change in any remaining parameter estimate greater than 15% as 
compared to the full model). This process of parsimonious model building was repeated 
for each of the four cohorts. 
 The c-statistics for the commercially insured hip replacement cohort, Medicare 
hip replacement cohort, commercially insured knee replacement cohort, and Medicare 
knee replacement cohort were 0.653, 0.673, 0.665 and 0.686, respectively. Results 
from these models are presented in Appendix 1. The parsimonious model for 
commercially insured hip replacement patients found that geographic region, type of 
insurance plan, prescription drug plan generosity, year of surgery, previous history of 
deep vein thrombosis, pulmonary embolism, atrial fibrillation, vascular diseases, end 
stage renal disease and concurrent use of statins were significantly associated with the 
choice of anticoagulant. The parsimonious model for Medicare total hip replacement 
patients found age, geographic region, type of insurance plan, prescription drug plan 
generosity, year of surgery, previous history of deep vein thrombosis, pulmonary 
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embolism, atrial fibrillation, diabetes, end stage renal disease and previous 
hospitalizations were significantly associated with the choice of anticoagulant.  
 Age, sex, geographic region, health insurance plan, prescription drug plan 
generosity, year of surgery, previous history of deep vein thrombosis, pulmonary 
embolism, diabetes, vascular diseases, end stage renal disease, clinically diagnosed 
obesity, concurrent use of statins, type of surgery setting and previous hospitalizations 
were found to be significantly associated with the choice of anticoagulant in 
commercially insured total knee replacement patients. The parsimonious model for 
Medicare total knee replacement cohort found that age, sex, geographic region, health 
insurance plan, prescription drug plan generosity, year of surgery, previous history of 
deep vein thrombosis, pulmonary embolism, vascular diseases, end stage renal 
disease, congestive heart failure, atrial fibrillation and the of surgery setting were 
significantly associated with the choice of anticoagulant. 
 
4.3 Aim 2: To compare the real world effectiveness of novel oral anticoagulant 
rivaroxaban with standard oral anticoagulant warfarin in venous 
thromboembolism prevention among patients with elective total hip or knee 
replacement surgery 
A total of 12,876 warfarin users and 10,892 rivaroxaban users with an elective 
total hip replacement were included in the commercially insured cohort (Figure 4-7) and 
7,416 warfarin users and 4,739 rivaroxaban users were included in the Medicare cohort 
(Figure 4-8). The baseline patient characteristics and standardized differences between 
warfarin and rivaroxaban users of the two hip replacement cohorts are presented in 
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Table 4-1. A total of 24,856 warfarin users and 21,398 rivaroxaban users with an 
elective total knee replacement were included in the commercially insured cohort 
(Figure 4-9) and 15,483 warfarin users and 8,997 rivaroxaban users were included in 
the Medicare cohort (Figure 4-10). The baseline patient characteristics and 
standardized differences between warfarin and rivaroxaban users of the two knee 
replacement cohorts are presented in Table 4-2. A detailed description of the baseline 
differences among the users is provided in section 4.2.2.  
VTE event rates were captured over 90 days following surgery and compared 
between patients initiating warfarin versus rivaroxaban. Table 4-5 shows the unadjusted 
results for VTE rates for patients initiating warfarin compared to rivaroxaban following 
an elective total hip or knee replacement surgery. Patients initiating rivaroxaban had, on 
average, lower rates of VTE in the 90 days following surgery. The unadjusted relative 
risks for DVT, PE and DVT and PE in the commercially insured elective hip replacement 
cohort and Medicare cohort were lower for rivaroxaban users compared to warfarin 
users (0.44 RR for DVT, 0.46 RR for PE and 0.53 RR for DVT and PE in commercial 
and 0.43 RR for DVT, 0.46 RR for PE and 0.32 RR for DVT and PE in Medicare 
cohorts, respectively).  
Among the total knee replacement cohorts, the unadjusted relative risks of DVT, 
PE and DVT and PE were lower in rivaroxaban users compared to warfarin users (0.35 
RR for DVT, 0.35 RR for PE and 0.39 RR for DVT and PE in commercial and 0.58 RR 
for DVT, 0.46 RR for PE and 0.44 RR for DVT and PE in Medicare cohorts, respectively 
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Table 4-5 Unadjusted VTE outcomes during 90 days post index period by therapy 
 Commercially insured Medicare 
 Warfarin 
n (%) 
Rivaroxaban 
n (%) 
P 
value 
Warfarin 
n (%) 
Rivaroxaban 
n (%) 
P value 
Total hip 
replacement 
n=12,876 n=10,892  n=7,416 n=4,739 
 
      DVT 198 (1.54) 59 (0.54) <0.001 223 
(3.01) 
82 (1.73) <0.001 
      PE 273 (2.12) 80 (0.73) <0.001 303 
(4.09) 
89 (1.88) <0.001 
      DVT and PE 36 (0.28) 12 (0.11) <0.01 74 (1.00) 21 (0.44) <0.001 
Total knee 
replacement 
n=24,856 n=21,398  n=15,483 n=8,997 
 
      DVT 537 (2.16) 204 (0.95) <0.001 557 
(3.60) 
139 (1.54) <0.001 
      PE 747 (3.01) 293 (1.37) <0.001 664 
(4.29) 
177 (1.97) <0.001 
      DVT and PE 132 (0.53)  60 (0.28) <0.001 168 
(1.09) 
31 (0.34) <0.001 
 
Model fit: 
The c, or concordance, statistic is often cited as a measure of the fit of the 
propensity score. It can take on values between 0.5 (classification no better than flipping 
a coin) and 1.0 (perfect classification).  The c-statistic measures the ability of a model to 
predict treatment status using the observed covariates.  Several reviews have reported 
a c-statistic greater than 0.90 indicates very good ability of the propensity score model 
to predict treatment status.  The c-statistic for the THR commercial and Medicare 
models were 0.76 and 0.78 and for the TKR commercial and Medicare models were 
0.77 and 0.79. Although a c-statistic is often reported, it provides no certainty that all 
measured confounders have been balanced between treatment groups.  Therefore, 
rather than letting the c-statistic guide selection of covariates into the propensity score 
model selection was informed by the conceptual model used to identify potentially 
important predictors of treatment selection (Figure 2-2). After model fit was evaluated, 
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the distribution of the propensity scores for patients initiating rivaroxaban vs. warfarin 
was evaluated using histograms. PS significantly overlapped between patients who 
initiated rivaroxaban and those who initiated warfarin except at the tails (Appendix 2). 
We used trimming (1st and 99th percentile) for the non-overlapping region. 
A logistic regression model was used to evaluate the association between initiation of 
rivaroxaban versus warfarin and having a VTE event during the follow-up period (Table 
4-6). As reflected in Table 4-6, among total hip replacement patients, warfarin users had 
significantly higher odds of deep vein thrombosis (OR 2.63, 95% CI 1.97-3.50 in 
commercial cohort and OR 1.78, 95% CI 1.38-2.29 in Medicare cohort) and pulmonary 
embolism (OR 2.60, 95% CI 2.04-3.31 in commercial cohort and OR 2.09, 95% CI 1.66-
2.65 in Medicare cohort). The odds of deep vein thrombosis (OR 2.06, 95% CI 1.76-
2.42 in commercial cohort and OR 2.21, 95% CI 1.84-2.65 in Medicare cohort) and 
pulmonary embolism (OR 2.03, 95% CI 1.78-2.33 in commercial cohort and OR 2.16, 
95% CI 1.84-2.55 in Medicare cohort) was also higher in the warfarin users in the total 
knee replacement commercial and Medicare cohorts. 
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Table 4-6 Association between initiating warfarin versus rivaroxaban and VTE 
event in propensity score adjusted cohort 
 
Commercially insured 
OR (95% CI) 
Medicare 
OR (95% CI) 
Total hip replacement   
      DVT 2.63* (1.98, 3.50) 1.78* (1.38-2.29) 
      PE 2.60* (2.04, 3.31) 2.09* (1.66-2.65) 
      DVT and PE 2.33* (1.25-4.37) 2.23* (1.39-3.58) 
Total knee replacement   
      DVT 2.06* (1.76-2.42) 2.21* (1.84-2.65) 
       PE 2.03* (1.78-2.33) 2.16* (1.84-2.55) 
      DVT and PE 1.59* (1.17-2.14) 2.75* (1.92-3.96) 
DVT- Deep vein thrombosis, PE – pulmonary embolism, OR – odds ratio, CI – confidence interval 
* denotes a statistically significant difference
 
 
Sensitivity analysis: 
To understand the effect of our assumption of prescription fills before the 
surgery, we restricted new users to only include those filling the prescription within 7 
days of the surgery (index date + 7). This reduced our sample size to 4,896 warfarin 
new users and 3,857 rivaroxaban new users in the commercially insured hip 
replacement cohort and 2,456 warfarin users and 947 rivaroxaban users in the hip 
replacement Medicare cohort. There were 10,459 warfarin users and 9,674 rivaroxaban 
users in the commercially insured total knee replacement cohort and 6,753 warfarin 
users and 2,989 rivaroxaban users in the Medicare cohort. Estimates from the 
sensitivity analysis are reported in table 4-7 and were found to be consistent with the 
primary model. 
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Table 4-7 Sensitivity analysis: Association between warfarin use versus 
rivaroxaban and VTE events in propensity score adjusted cohort 
 
Commercially insured 
OR (95% CI) 
Medicare 
OR (95% CI) 
Total hip replacement   
      DVT 2.74* (1.87, 3.68) 2.10* (1.56-2.45) 
      PE 2.58* (1.87, 3.29) 2.32* (1.78-2.71) 
      DVT and PE 2.34* (1.19-3.12) 1.98* (1.54-2.67) 
Total knee replacement   
      DVT 2.53* (1.87-2.86) 2.42* (1.96-2.97) 
       PE 2.32* (1.86-3.20) 2.56* (1.65-3.21) 
      DVT and PE 2.01* (1.56-2.39) 2.38* (1.64-2.76) 
DVT- Deep vein thrombosis, PE – pulmonary embolism, OR – odds ratio, CI – confidence interval 
* denotes a statistically significant difference
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4.4 Aim 3: To compare the safety of novel oral anticoagulant rivaroxaban with 
standard oral anticoagulant warfarin in venous thromboembolism prevention 
among patients with elective total hip or knee replacement surgery 
 
A total of 12,876 warfarin users and 10,892 rivaroxaban users with an elective 
total hip replacement were included in the commercially insured cohort (Figure 4-7) and 
7,416 warfarin users and 4,739 rivaroxaban users were included in the Medicare cohort 
(Figure 4-8). The baseline patient characteristics and standardized differences between 
warfarin and rivaroxaban users of the two hip replacement cohorts are presented in 
Table 4-1. A total of 24,856 warfarin users and 21,398 rivaroxaban users with an 
elective total knee replacement were included in the commercially insured cohort 
(Figure 4-9) and 15,483 warfarin users and 8,997 rivaroxaban users were included in 
the Medicare cohort (Figure 4-10). The baseline patient characteristics and 
standardized differences between warfarin and rivaroxaban users of the two knee 
replacement cohorts are presented in Table 4-2. A detailed description of the baseline 
differences among the users is provided in section 4.2.2.  
Bleeding event rates were captured over 90 days following surgery and 
compared between patients initiating warfarin versus rivaroxaban.  Table 4-8 shows the 
unadjusted results for bleeding rates for patients initiating warfarin compared to 
rivaroxaban following an elective hip or knee replacement surgery. The unadjusted 
relative risks for any bleeding in the commercially insured elective hip replacement 
cohort and Medicare cohort were the same for rivaroxaban users compared to warfarin 
users (relative risk 1.01 RR). The unadjusted relative risk of gastrointestinal bleeding 
was lower in rivaroxaban users compared to warfarin users (RR 0.95 and RR 0.97 in 
 90 
 
commercial and Medicare cohorts, respectively). The unadjusted relative risk of 
intracranial hemorrhage was lower in the commercial cohort but higher in the Medicare 
cohort (RR 0.59 in commercial cohort, RR 1.34 in Medicare cohort). The unadjusted 
relative risk of major bleeding was almost the same across warfarin and rivaroxaban 
users (RR 1.07 in commercial cohort and RR 1.13 in Medicare cohort). The unadjusted 
relative risk of post-operative infection was lower in rivaroxaban users compared to 
warfarin users (RR 0.70 in commercial cohort and 0.57 in Medicare cohort) 
Among the total knee replacement commercial cohort, unadjusted relative risks 
of any bleeding, GI bleeding and ICH were lower in rivaroxaban users compared to 
warfarin users (0.84 RR for any bleeding, 0.78 RR for GI bleeding, and 0.44 RR for 
ICH). In the Medicare cohort, the unadjusted risk of bleeding was the same between 
warfarin and rivaroxaban users (RR 0.99), but the risk of GI bleeding was slightly higher 
(RR 1.13) and that of intracranial hemorrhage was lower (RR .65). The unadjusted 
relative risk of major bleeding was lower in both the cohorts (RR 0.89 in commercial 
cohort and RR 0.81 in Medicare cohort). The unadjusted risk of perioperative joint 
infection was also slightly lower in the rivaroxaban cohorts (RR 0.92 in commercial 
cohort and 0.95 in Medicare cohort). 
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Table 4-8 Unadjusted bleeding outcomes during 90 days post index period by 
therapy 
 Commercially insured Medicare 
 Warfarin 
n (%) 
Rivaroxaban 
n (%) 
P 
value 
Warfarin 
n (%) 
Rivaroxaban 
n (%) 
P 
value 
Total hip 
replacement 
n=12,876 n=10,892  n=7,416 n=4,739 
 
  Any bleeding 68 (0.53) 58 (0.53) 0.96 87 (1.17) 56 (1.18) 0.97 
  GI bleeding 35 (0.27) 28 (0.26) 0.83 58 (0.78) 36 (0.76) 0.89 
  ICH 4 (0.03) 2 (0.02) - 7 (0.09) 6 (0.13) 0.60 
  Major bleeding 33 (0.26)  30 (0.28) 0.77 29 (0.39) 21 (0.44) 0.66 
  PJI 113 (0.88) 67 (0.62) 0.02 63 (0.85) 23 (0.49) 0.02 
Total knee 
replacement 
n=24,856 n=21,398  n=15,483 n=8,997 
 
  Any bleeding 173 (0.70) 125 (0.58) 0.13 211 (1.36) 121 (1.34) 0.91 
  GI bleeding 79 (0.32) 53 (0.25) 0.16 117 (0.76) 77 (0.86) 0.39 
  ICH 16 (0.06) 6 (0.03) 0.07 16 (0.1) 6 (0.07) 0.36 
  Major bleeding 94 (0.38) 72 (0.34) 0.45 94 (0.61) 44 (0.49) 0.23 
  PJI 175 (0.70) 139 (0.65) 0.48 103 (0.67) 57 (0.63) 0.77 
*GI bleeding– gastrointestinal bleeding, ICH – intracranial hemorrhage, PJI – postoperative joint 
infection 
 
 
As shown in Table 4-9, among total hip replacement patients, warfarin users had 
slightly lower odds of any bleeding compared to rivaroxaban users (OR 0.91, 95% CI 
0.65-1.28 in commercial cohort and OR 0.91, 95% CI 0.66 -1.27 in Medicare cohort). 
However, these were statistically insignificant.  The odds of GI bleeding (OR 0.99, 95% 
CI 0.61 -1.64 in commercial cohort and OR 0.92, 95% CI 0.62 -1.37 in Medicare cohort), 
intracranial hemorrhage (OR 0.78, 95% CI 0.26 -2.37 in Medicare cohort) and major 
bleeding (OR 0.84, 95% CI 0.52-1.35 in commercial cohort and OR 0.86, 95% CI 0.49-
1.51 in Medicare cohort), although statistically insignificant, were also lower in warfarin 
users. The odds of postoperative joint infection (OR 1.57, 95% CI 1.16 -2.13 in 
commercial cohort and OR 1.79, 95% CI 1.14-2.81 in Medicare cohort) was significantly 
higher in the warfarin users compared to rivaroxaban users. 
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Table 4-9 Association between initiating warfarin versus rivaroxaban and 
bleeding event in propensity score adjusted cohort 
 
Commercially insured 
OR (95% CI) 
Medicare 
OR (95% CI) 
Total hip replacement   
      Any bleeding 0.91 (0.65-1.29) 0.91 (0.66-1.27) 
      GI bleeding 0.99 (0.61 -1.64) 0.92 (0.62 -1.37) 
      ICH N/A┼ 0.78 (0.26 -2.37) 
      Major bleeding 0.84 (0.52-1.35) 0.86 (0.49-1.51) 
      PJI 1.57* (1.16 -2.13) 1.79* (1.14-2.81) 
Total knee replacement   
      Any bleeding 1.26* (1.00-1.57) 1.00 (0.81-1.24) 
       GI bleeding 1.39 (0.98-1.97) 0.86 (0.65-1.13) 
       ICH 2.70* (1.05-6.91) 1.43 (0.59-3.47) 
       Major bleeding 1.17 (0.87-1.56) 1.27 (0.90-1.80) 
       PJI 1.07 (0.86-1.33) 0.98 (0.72-1.34) 
GI bleeding– gastrointestinal bleeding, ICH – intracranial hemorrhage, PJI – postoperative joint infection, 
OR – odds ratio, CI – confidence interval 
* denotes a statistically significant difference 
┼ the number of events was less than 5 and was not modelled due to power considerations 
 
 
  Among total knee replacement patients, warfarin users had the same odds of any 
bleeding compared to rivaroxaban users (OR 1.26, 95% CI 1.00-1.57 in commercial 
cohort and OR 1.00, 95% CI 0.81 -1.24 in Medicare cohort). The odds of GI bleeding 
(OR 1.39, 95% CI 0.98 -1.97 in commercial cohort and OR 0.86, 95% CI 0.65 -1.13 in 
Medicare cohort), intracranial hemorrhage (OR 2.70, 95% CI 1.05 -6.91 in commercial 
cohort and OR 1.43, 95% CI 0.59-3.47 Medicare cohort) and major bleeding (OR 1.17, 
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95% CI 0.87-1.56 in commercial cohort and OR 1.27, 95% CI 0.90-1.80 in Medicare 
cohort), although statistically insignificant, were slightly higher in warfarin users. The 
odds of postoperative joint infection (OR 1.07, 95% CI 0.86 -1.33 in commercial cohort 
and OR 0.98, 95% CI 0.72-1.34 in Medicare cohort) was the same among warfarin 
users compared to rivaroxaban users. 
 
Sensitivity analysis: 
To understand the effect of our assumption of prescription fills before the 
surgery, we restricted new users to only include those filling the prescription within 7 
days of the surgery (index date + 7). This reduced our sample size to 4,896 warfarin 
new users and 3,857 rivaroxaban new users in the commercially insured hip 
replacement cohort and 2,456 warfarin users and 947 rivaroxaban users in the hip 
replacement Medicare cohort. There were 10,459 warfarin users and 9,674 rivaroxaban 
users in the commercially insured total knee replacement cohort and 6,753 warfarin 
users and 2,989 rivaroxaban users in the Medicare cohort. The rate of intracranial 
hemorrhage in the sensitivity cohort was too low to perform sensitivity analysis. 
Estimates from the sensitivity analysis are reported in table 4-10 and were found to be 
consistent with the primary model. 
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Table 4-10 Sensitivity analysis: Association between warfarin use versus 
rivaroxaban and bleeding events in propensity score adjusted cohort 
 
Commercially insured 
OR (95% CI) 
Medicare 
OR (95% CI) 
Total hip replacement   
      Any bleeding 1.02 (0.68-1.23) 0.98 (0.658-1.267) 
      GI bleeding 0.98 (0.67 -1.39) 0.97 (0.56-1.62) 
      Major bleeding 0.99 (0.62-1.23) 0.96 (0.56-1.24) 
      PJI 1.23* (1.01 -1.87) 1.21* (1.08-1.89) 
Total knee replacement   
      Any bleeding 1.10 (0.76 -1.45) 0.99 (0.78-1.21) 
       GI bleeding 1.40 (0.87-2.10) 1.02 (0.66-1.45) 
       Major bleeding 1.23 (0.89-1.84) 1.02 (0.78-1.34) 
       PJI 1.02 (0.67-1.48) 1.01 (0.89-1.53) 
GI bleeding– gastrointestinal bleeding, ICH – intracranial hemorrhage, PJI – postoperative joint infection, 
OR – odds ratio, CI – confidence interval 
* denotes a statistically significant difference 
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Chapter 5 : Discussion 
 
 
This study describes the trends in utilization of anticoagulants after an elective 
total hip or knee replacement surgery over time. Additionally, it explores the association 
of different patient characteristics with the type of anticoagulant prescribed. It also 
analyses the comparative effectiveness and safety of the newer oral anticoagulant, 
rivaroxaban with the standard oral anticoagulant, warfarin. 
This study has four main findings. First, since their introduction in the US market 
in 2011, newer oral anticoagulants, particularly rivaroxaban, have been quickly adopted 
into clinical practice in post-surgery in orthopedic patients. Rivaroxaban replaced 21% 
of warfarin prescriptions in under a year and up to 50% in three years. This could be 
attributed to the perceived benefits of newer oral anticoagulants over warfarin by 
physicians. A recent study conducted in atrial fibrillation patients regarding physician 
and patient preferences for oral anticoagulants showed that almost half of the surveyed 
physicians spontaneously stated rivaroxaban as their preferred agent for 
anticoagulation.122 It is interesting to note that this study did not show any patient 
preferences between warfarin, rivaroxaban and apixaban. We also notice a steady 
decline in the use of non-oral anticoagulants such as heparins over time. The extent to 
which newer oral anticoagulants will replace current therapies and continue to expand 
their market share depends upon the balance between benefits such as greater dosing 
convenience and fewer drug-drug interactions and the risks such as uncertainties 
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regarding their comparative safety and effectiveness, established beyond the clinical 
trials used to gain their market approval.  
Second, we found that the choice of anticoagulant was influenced by a mix of 
predisposing, enabling and need factors. Females were less likely to be prescribed 
rivaroxaban compared to males. One study found that women have fewer DVT events 
and more bleeds than men during the course of anticoagulation therapy.123 If bleeding is 
a safety concern in patients, warfarin is preferred over rivaroxaban due to the availability 
of reversal agents. This could explain some of the reasons for the differences in 
prescribing by gender. Patients having surgeries in the recent years had higher odds of 
rivaroxaban use compared to those having surgery closer to 2011. Over time, more 
studies have been published establishing the comparative effectiveness and safety of 
newer anticoagulants through meta-analysis of clinical trials. This shift in prescribing 
pattern over time could be due to more evidence generation. Type of health plan was 
also found to be a significant predictor of rivaroxaban initiation in these patients. Plans 
with capitated health plans had a lower rate of rivaroxaban prescription and could be 
due to plans trying to keep their costs lower. Previous research has shown that 
capitated payment plans encourage underuse of expensive services.124 However, this 
finding should be interpreted with caution as a very small percentage of our sample size 
(<1%) was enrolled in the capitated plan which could result in insufficient power to 
support these findings. 
In addition to these factors, our analyses found clinical comorbidities such as a 
history of deep vein thrombosis, pulmonary embolism, cardiovascular diseases and 
renal impairment also affected the choice of anticoagulant. Patients with renal 
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impairment were less likely to be prescribed rivaroxaban in both, commercially insured 
as well as Medicare cohorts. Physicians are advised to use caution when using 
rivaroxaban in patients with kidney disease due increased half-life and lack of reversal 
agents.125 While the presence of deep vein thrombosis, pulmonary embolism and 
cardiovascular diseases was associated with an increased use of rivaroxaban in 
commercially insured patients, it was associated with a decreased use of rivaroxaban in 
Medicare patients. This difference between the two cohorts could be due to other 
differences in these patient populations such age and overall health status. Physicians 
have been reported to use less aggressive treatment strategies in elder people in other 
therapeutic areas such as rheumatoid arthritis.126 This also corresponds to on average, 
relatively lower uptake of rivaroxaban in the Medicare population compared to 
commercially insured population as observed in aim 1a over time. Future research 
should be conducted to examine the efficacy and safety of anticoagulants in elderly 
patients to address physician concerns.   
 Our study used real-world claims data from a US population to compare the 
safety and effectiveness of rivaroxaban with warfarin therapy in patients with elective 
total hip and knee replacements. Our analyses show that the odds of deep vein 
thrombosis and pulmonary embolism were significantly lower among rivaroxaban users 
compared to warfarin users. To our knowledge, no studies have directly compared the 
safety and effectiveness of rivaroxaban with warfarin following hip or knee replacement 
surgery. However, clinical trials that have compared the efficacy of heparins 
(enoxaparin and dalteparin) found them to be superior to warfarin in terms of 
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efficacy.127,128 Also, clinical trials in elective orthopedic surgery patients found 
rivaroxaban to be superior in preventing VTE compared to enoxaparin.129  
Orthopedic surgery practice in the area of venous thromboembolism prophylaxis 
has often been guided by concerns over bleeding, especially with the newer oral 
anticoagulants.130 Our study found that the risk of bleeding among rivaroxaban users 
was not significantly different than warfarin users. Different clinical trials have evaluated 
the bleeding risk of rivaroxaban, but have different conclusions.131-135 It is not possible to 
compare safety data from different clinical trials because there is no standardized 
definition of bleeding that has been used uniformly in all randomized controlled trials. 
Differences in reported major bleeding rates among pivotal trials for the newer 
anticoagulants are driven to a large extent by the definitions of bleeding used in the 
trials, by the regimens utilized and partially by the properties of the anticoagulants 
themselves. Another concern that orthopedic surgeons often have with anticoagulants 
after a hip or knee replacement surgery is their effect on the rate of postoperative joint 
infection. We observed that the risk of postoperative joint infection is significantly lower 
in rivaroxaban users compared to warfarin users.  No previous study has analyzed the 
risk of perioperative joint infection among rivaroxaban and warfarin users. One study 
that compared rivaroxaban to enoxaparin found similar rates of infection between the 
two agents.  
 
Limitations: 
 
The findings of our study should be viewed in light of its limitations and strengths. 
To assess the treatment exposure, we required the patient to survive the surgical 
hospitalization which could induce survival bias. Therefore, we can generalize our 
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findings only to those who survive initial hip or knee replacement surgery related 
hospitalization. To understand the effect of survival bias on our findings, we analyzed 
the number of people lost to follow up (as defined by disenrollment in the three months 
following the surgery) in the rivaroxaban group versus the warfarin group in each of the 
surgery cohorts. We found no patients lost in either the warfarin or the rivaroxaban 
group among the total hip replacement surgery patients. Among the total knee 
replacement Medicare cohort, we found 1 person (0.004%) dis-enrolled in the month 
following the surgery in the warfarin cohort compared to no loss during follow up period 
in the rivaroxaban cohort. There were no patients lost to follow up in either of the two 
treatment groups in the commercially insured total knee replacement cohort. Based on 
this analysis, we assumed that there was little chance of differential survival among the 
two treatment options in either of the surgery cohorts.  
Our results are based on patients in the TruvenHealth Marketscan databases 
and may not be generalizable to the entire commercially insured or general population. 
Our study also only included patients with supplemental Medicare insurance and these 
individuals are not representative of the entire Medicare population. Furthermore, there 
are several limitations of claims databases that must be acknowledged. Since, the 
primary function of claims data is collection and adjudication of insurance claims, they 
do not contain any information about over-the-counter drug use or medication use 
through secondary sources such as physician samples or mail order pharmacies. Since 
aspirin is a newly emerging anticoagulant that is available over-the-counter, there is a 
potential for concurrent use or switching from other pharmacological agents that was 
 100 
 
unobservable in our data. Claims data relies on accuracy in medical coding and errors 
in billing codes could lead to inaccuracies in the event rate.  
Lastly, the observed differences in the risk of the outcome (or lack thereof) 
between the two treatment groups could be due to confounding caused by imbalance of 
other covariates. To overcome this limitation, we used IPTW to balance covariates in 
the baseline period. However, this was only limited to observable confounders. We did 
not have access to some of the known potential confounders such as body mass index. 
Despite these limitations, our study provides a comprehensive overview of the 
utilization pattern of anticoagulants that helps us understand the changes in clinical 
practice over time. It also helps us quantify the uptake of newer oral anticoagulants in 
these patients and tries to provide meaningful answer to the important clinical question 
related to the best strategies of reducing VTE and bleeding risk in patients with hip or 
knee replacement. Lastly, our study provides us with an insight into the real-world VTE 
and symptomatic bleeding complication rates among the different anticoagulants. 
 
Conclusion: 
The results from this dissertation suggest that treatment with rivaroxaban may 
help in reducing the risk of incident VTE events without any significant increase in the 
risk of bleeding or post-operative joint infection compared to warfarin treatment in 
patients with a hip or knee replacement surgery. Future studies with larger sample size 
are recommended to confirm findings from our study.
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APPENDICES 
 
Appendix 1: SAS output for purposeful selection of variables 
 
FINAL MODEL FOR COMMERCIALLY INSURED TOTAL HIP REPLACEMENT COHORT 
                       
Model Information 
 
Response Variable                      rivaroxaban           
Number of Response Levels     2 
Model                                           binary logit 
Optimization Technique           Fisher's scoring 
 
 
Number of Observations Read       23768 
Number of Observations Used       23768 
 
 
           Response Profile 
 
 Ordered                               Total 
   Value        rivaroxaban     Frequency 
 
       1                   1                  10892 
       2                   0                  12876 
 
Probability modeled is rivaroxaban=1. 
 
 
Final main effects model - some significant noncandidates 
 
The LOGISTIC Procedure 
 
                    Model Convergence Status 
 
         Convergence criterion (GCONV=1E-8) satisfied. 
 
 
       Deviance and Pearson Goodness-of-Fit Statistics 
 
Criterion                 Value        DF         Value/DF     Pr > ChiSq 
 
Deviance          2626.4265     2035       1.2906         <.0001 
Pearson            2179.1469     2035       1.0708         0.0133 
 
Number of unique profiles: 2057 
 
 
 
         Model Fit Statistics 
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Hosmer and Lemeshow Goodness-of-Fit Test 
 
Chi-Square       DF     Pr > ChiSq 
 
   45.4705        8         <.0001 
 
 
AIC              32785.640      30856.969 
SC                32793.716      31066.948 
-2 Log L       32783.640      30804.969 
 
 
        Testing Global Null Hypothesis: BETA=0 
 
Test                           Chi-Square       DF     Pr > ChiSq 
 
Likelihood Ratio      1978.6707       25         <.0001 
Score                         1862.7941       25         <.0001 
Wald                          1695.2225       25         <.0001 
 
 
 
          
 
                Analysis of Maximum Likelihood Estimates 
 
                                    Standard          Wald 
Parameter         DF    Estimate       Error    Chi-Square    Pr > ChiSq 
 
Intercept             1     -1.1695       0.3358       12.1337        0.0005 
rxgen     1            1     -0.00855     0.0633        0.0182        0.8926 
rxgen     2            1     -0.0286       0.0542        0.2785        0.5977 
rxgen     3            1     -0.0537       0.0573        0.8803        0.3481 
Statin    0             1      0.0507       0.0313        2.6322        0.1047 
DVT       0             1      0.3136       0.1760        3.1739        0.0748 
PE        0               1      0.2814       0.1780        2.4988        0.1139 
indexyr   2011     1     -1.7623      0.0659       715.1200      <.0001 
indexyr   2012     1     -0.6611      0.0550       144.3466      <.0001 
indexyr   2013     1     -0.3190      0.0556       32.9672        <.0001 
indexyr   2014     1     -0.0837      0.0576        2.1082        0.1465 
AF        0               1      0.2055      0.1083        3.6013        0.0577 
REGION    1         1     -0.0167      0.2078        0.0065        0.9358 
REGION    2         1      0.4722      0.2068        5.2126        0.0224 
REGION    3        1      0.8280      0.2063       16.1052        <.0001 
REGION    4        1      0.5630      0.2074        7.3685        0.0066 
PLANTYP   0        1      0.2250      0.1065        4.4588        0.0347 
PLANTYP   2        1     -0.0346      0.0984        0.1238        0.7250 
PLANTYP   3        1     -0.0344      0.1566        0.0482        0.8262 
PLANTYP   4        1     -0.3124      0.0835       13.9829        0.0002 
PLANTYP   5        1     -0.1904      0.0882        4.6620        0.0308 
PLANTYP   6        1     -0.0278      0.0720        0.1484        0.7001 
PLANTYP   7        1     -0.6968      0.2231        9.7563        0.0018 
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PLANTYP   8        1     -0.0918      0.0851        1.1630        0.2809 
ESRD      0            1      0.3560      0.0990       12.9178        0.0003 
Vascular  0          1     -0.0890      0.0518        2.9532        0.0857 
 
 
                  Odds Ratio Estimates 
 
                            Point          95% Wald 
Effect                   Estimate      Confidence Limits 
 
rxgen    1 vs 4             0.991       0.876       1.122 
rxgen    2 vs 4             0.972       0.874       1.081 
rxgen    3 vs 4             0.948       0.847       1.060 
Statin   0 vs 1             1.052       0.989       1.119 
DVT      0 vs 1             1.368       0.969       1.932 
PE       0 vs 1             1.325       0.935       1.878 
indexyr  2011 vs 2015       0.172       0.151       0.195 
indexyr  2012 vs 2015       0.516       0.464       0.575 
indexyr  2013 vs 2015       0.727       0.652       0.811 
indexyr  2014 vs 2015       0.920       0.821       1.030 
AF       0 vs 1             1.228       0.993       1.518 
REGION   1 vs 5             0.983       0.654       1.478 
REGION   2 vs 5             1.603       1.069       2.405 
REGION   3 vs 5             2.289       1.527       3.429 
REGION   4 vs 5             1.756       1.169       2.637 
PLANTYP  0 vs 9             1.252       1.016       1.543 
PLANTYP  2 vs 9             0.966       0.797       1.171 
PLANTYP  3 vs 9             0.966       0.711       1.313 
PLANTYP  4 vs 9             0.732       0.621       0.862 
PLANTYP  5 vs 9             0.827       0.695       0.983 
PLANTYP  6 vs 9             0.973       0.845       1.120 
PLANTYP  7 vs 9             0.498       0.322       0.771 
PLANTYP  8 vs 9             0.912       0.772       1.078 
ESRD     0 vs 1             1.428       1.176       1.733 
Vascular 0 vs 1             0.915       0.826       1.013 
 
 
Association of Predicted Probabilities and Observed Responses 
 
Percent Concordant         65.0    Somers' D    0.306 
Percent Discordant         34.4    Gamma        0.307 
Percent Tied                0.5    Tau-a        0.152 
Pairs                 140245392    c            0.653 
 
 
 
 
FINAL MODEL FOR TOTAL HIP REPLACEMENT IN MEDICARE PATIENTS 
 
Final main effects model - some significant noncandidates 
 
The LOGISTIC Procedure 
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                      Model Information 
 
Response Variable                      rivaroxaban           
Number of Response Levels     2 
Model                                           binary logit 
Optimization Technique        Fisher's scoring 
 
 
Number of Observations Read       12155 
Number of Observations Used       12155 
 
 
           Response Profile 
 
 Ordered                         Total 
   Value     rivaroxaban     Frequency 
 
       1            1             4739 
       2            0             7416 
 
Probability modeled is rivaroxaban=1. 
 
 
                    Model Convergence Status 
 
         Convergence criterion (GCONV=1E-8) satisfied. 
 
 
       Deviance and Pearson Goodness-of-Fit Statistics 
 
Criterion          Value       DF     Value/DF     Pr > ChiSq 
 
Deviance       6441.2121     5408       1.1911         <.0001 
Pearson        5302.4193     5408       0.9805         0.8451 
 
Number of unique profiles: 5430 
        Model Fit Statistics 
 
                             Intercept 
              Intercept            and 
Criterion          Only     Covariates 
 
AIC           16257.968      15120.248 
SC            16265.374      15320.196 
-2 Log L      16255.968      15066.248 
 
 
        Testing Global Null Hypothesis: BETA=0 
 
Test                 Chi-Square       DF     Pr > ChiSq 
 
Likelihood Ratio      1189.7204       26         <.0001 
Score                 1097.6999       26         <.0001 
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Wald                   974.1887       26         <.0001 
 
 
         Type 3 Analysis of Effects 
 
                          Wald 
Effect        DF    Chi-Square    Pr > ChiSq 
 
agevar         1       17.2672        <.0001 
REGION         4      147.0847        <.0001 
PLANTYP        8       11.3678        0.1817 
rxgen          3        5.5685        0.1346 
indexyr        4      769.5827        <.0001 
Diabetes       1        3.0902        0.0788 
DVT            1        7.9440        0.0048 
PE             1        4.4031        0.0359 
AF             1       21.5116        <.0001 
ESRD           1        7.6644        0.0056 
cat_hosp       1        2.7171        0.0993 
 
 
 
  
 
                Analysis of Maximum Likelihood Estimates 
 
                                    Standard          Wald 
Parameter         DF    Estimate       Error    Chi-Square    Pr > ChiSq 
 
Intercept          1     -1.0814      0.7126        2.3028        0.1291 
agevar             1     -0.0128     0.00308       17.2672        <.0001 
REGION    1        1      0.3037      0.3398        0.7989        0.3714 
REGION    2        1      0.5622      0.3389        2.7511        0.0972 
REGION    3        1      0.9665      0.3394        8.1099        0.0044 
REGION    4        1      0.6378      0.3408        3.5024        0.0613 
PLANTYP   0        1      0.4452      0.5486        0.6584        0.4171 
PLANTYP   2        1      0.4531      0.5162        0.7706        0.3800 
PLANTYP   3        1      0.8198      0.6632        1.5282        0.2164 
PLANTYP   4        1      0.2901      0.5193        0.3121        0.5764 
PLANTYP   5        1      0.4931      0.5245        0.8840        0.3471 
PLANTYP   6        1      0.4654      0.5160        0.8137        0.3670 
PLANTYP   7        1      0.0344      0.6670        0.0027        0.9589 
PLANTYP   8        1      0.0598      0.5745        0.0108        0.9171 
rxgen     1        1     -0.1188      0.1422        0.6979        0.4035 
rxgen     2        1     -0.2305      0.1235        3.4838        0.0620 
rxgen     3        1     -0.1830      0.1273        2.0671        0.1505 
indexyr   2011     1     -2.2052      0.0975      511.7599        <.0001 
indexyr   2012     1     -0.9695      0.0746      168.8098        <.0001 
indexyr   2013     1     -0.5827      0.0748       60.6383        <.0001 
indexyr   2014     1     -0.1575      0.0777        4.1127        0.0426 
Diabetes  0        1      0.0904      0.0514        3.0902        0.0788 
DVT       0        1      0.5704      0.2024        7.9440        0.0048 
PE        0        1      0.3605      0.1718        4.4031        0.0359 
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AF        0        1      0.3999      0.0862       21.5116        <.0001 
ESRD      0        1      0.2389      0.0863        7.6644        0.0056 
cat_hosp  0        1     -0.1388      0.0842        2.7171        0.0993 
 
 
                   
Odds Ratio Estimates 
 
                            Point          95% Wald 
Effect                   Estimate      Confidence Limits 
 
agevar                      0.987       0.981       0.993 
REGION   1 vs 5             1.355       0.696       2.637 
REGION   2 vs 5             1.755       0.903       3.409 
REGION   3 vs 5             2.629       1.352       5.112 
REGION   4 vs 5             1.892       0.970       3.691 
PLANTYP  0 vs 9             1.561       0.533       4.575 
PLANTYP  2 vs 9             1.573       0.572       4.326 
PLANTYP  3 vs 9             2.270       0.619       8.328 
PLANTYP  4 vs 9             1.337       0.483       3.699 
PLANTYP  5 vs 9             1.637       0.586       4.577 
PLANTYP  6 vs 9             1.593       0.579       4.379 
PLANTYP  7 vs 9             1.035       0.280       3.825 
PLANTYP  8 vs 9             1.062       0.344       3.273 
rxgen    1 vs 4             0.888       0.672       1.173 
rxgen    2 vs 4             0.794       0.623       1.012 
rxgen    3 vs 4             0.833       0.649       1.069 
indexyr  2011 vs 2015       0.110       0.091       0.133 
indexyr  2012 vs 2015       0.379       0.328       0.439 
indexyr  2013 vs 2015       0.558       0.482       0.647 
indexyr  2014 vs 2015       0.854       0.734       0.995 
Diabetes 0 vs 1             1.095       0.990       1.211 
DVT      0 vs 1             1.769       1.190       2.630 
PE       0 vs 1             1.434       1.024       2.008 
AF       0 vs 1             1.492       1.260       1.766 
ESRD     0 vs 1             1.270       1.072       1.504 
cat_hosp 0 vs 1             0.870       0.738       1.027 
 
 
Association of Predicted Probabilities and Observed Responses 
 
Percent Concordant        67.3    Somers' D    0.347 
Percent Discordant        32.7    Gamma        0.347 
Percent Tied               0.0    Tau-a        0.165 
Pairs                 35144424    c            0.673 
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FINAL MODEL FOR COMMERCIALLY INSURED TOTAL KNEE REPLACEMENT COHORT 
 
Model Information 
 
Response Variable             rivaroxaban           
Number of Response Levels     2 
Model                         binary logit 
Optimization Technique        Fisher's scoring 
Number of Observations Read       46254 
Number of Observations Used       46254 
 
 
           Response Profile 
 
 Ordered                         Total 
   Value     rivaroxaban     Frequency 
 
       1            1            21398 
       2            0            24856 
 
Probability modeled is rivaroxaban=1. 
 
 
                    Model Convergence Status 
 
         Convergence criterion (GCONV=1E-8) satisfied. 
 
 
       Deviance and Pearson Goodness-of-Fit Statistics 
 
Criterion          Value       DF     Value/DF     Pr > ChiSq 
 
Deviance      30567.9857     24E3       1.2623         <.0001 
Pearson       24022.8002     24E3       0.9920         0.8110 
 
Number of unique profiles: 24247 
 
 
         Model Fit Statistics 
 
                               
Criterion        Intercept Only     Intercept  & Covariates 
 
       AIC           63864.894              59595.863 
       SC             63873.636              59858.120 
     -2 Log L      63862.894              59535.863 
 
 
        Testing Global Null Hypothesis: BETA=0 
 
Test                 Chi-Square       DF     Pr > ChiSq 
 
Likelihood Ratio      4327.3441       30         <.0001 
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Score                 4077.4448       30         <.0001 
Wald                  3717.6778       30         <.0001 
 
 
         Type 3 Analysis of Effects 
 
                           Wald 
Effect         DF    Chi-Square    Pr > ChiSq 
 
agevar          1       76.0972        <.0001 
SEX             1        9.9260        0.0016 
REGION          4     1431.6074        <.0001 
PLANTYP         8      104.5396        <.0001 
rxgen           3        2.6590        0.4472 
indexyr         4     2218.6674        <.0001 
DVT             1        6.5044        0.0108 
PE              1       30.1100        <.0001 
Diabetes        1        0.7106        0.3992 
Vascular        1        1.5429        0.2142 
ESRD            1       11.8820        0.0006 
Obese           1        5.0734        0.0243 
INPATIENT       1        5.8450        0.0156 
cat_hosp        1        4.2508        0.0392 
Statin          1        0.5446        0.4605 
 
 
                Analysis of Maximum Likelihood Estimates 
 
                                    Standard          Wald 
Parameter         DF    Estimate       Error    Chi-Square    Pr > ChiSq 
 
Intercept          1     -0.3881      0.2514        2.3843        0.1226 
agevar             1     -0.0162     0.00186       76.0972        <.0001 
SEX       1        1      0.0639      0.0203        9.9260        0.0016 
REGION    1        1     -0.1208      0.1434        0.7095        0.3996 
REGION    2        1      0.5478      0.1422       14.8459        0.0001 
REGION    3        1      1.0329      0.1417       53.1420        <.0001 
REGION    4        1      0.7613      0.1429       28.3654        <.0001 
PLANTYP   0        1      0.3110      0.0792       15.4015        <.0001 
PLANTYP   2        1     -0.0401      0.0717        0.3129        0.5759 
PLANTYP   3        1     -0.0724      0.1178        0.3781        0.5386 
PLANTYP   4        1     -0.3063      0.0647       22.4233        <.0001 
PLANTYP   5        1     -0.0588      0.0668        0.7731        0.3793 
PLANTYP   6        1     -0.0440      0.0564        0.6087        0.4353 
PLANTYP   7        1     -0.3462      0.1626        4.5310        0.0333 
PLANTYP   8        1     -0.0640      0.0656        0.9509        0.3295 
rxgen     1        1      0.0533      0.0514        1.0759        0.2996 
rxgen     2        1     0.00111      0.0444        0.0006        0.9800 
rxgen     3        1     0.00726      0.0464        0.0244        0.8758 
indexyr   2011     1     -1.7018      0.0460     1366.0887        <.0001 
indexyr   2012     1     -0.6424      0.0390      271.9377        <.0001 
indexyr   2013     1     -0.3707      0.0394       88.5279        <.0001 
indexyr   2014     1     -0.1098      0.0405        7.3380        0.0068 
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DVT       0        1      0.2958      0.1160        6.5044        0.0108 
PE        0        1      0.5997      0.1093       30.1100        <.0001 
Diabetes  0        1      0.0224      0.0265        0.7106        0.3992 
Vascular  0        1     -0.0441      0.0355        1.5429        0.2142 
ESRD      0        1      0.2463      0.0715       11.8820        0.0006 
Obese     0        1      0.0697      0.0309        5.0734        0.0243 
INPATIENT 0        1     -0.1714      0.0709        5.8450        0.0156 
cat_hosp  0        1     -0.1201      0.0583        4.2508        0.0392 
Statin    0        1      0.0162      0.0220        0.5446        0.4605 
 
 
                   Odds Ratio Estimates 
 
                             Point          95% Wald 
Effect                    Estimate      Confidence Limits 
 
agevar                       0.984       0.980       0.988 
SEX       1 vs 2             1.066       1.024       1.109 
REGION    1 vs 5             0.886       0.669       1.174 
REGION    2 vs 5             1.729       1.309       2.285 
REGION    3 vs 5             2.809       2.128       3.709 
REGION    4 vs 5             2.141       1.618       2.833 
PLANTYP   0 vs 9             1.365       1.168       1.594 
PLANTYP   2 vs 9             0.961       0.835       1.106 
PLANTYP   3 vs 9             0.930       0.738       1.172 
PLANTYP   4 vs 9             0.736       0.649       0.836 
PLANTYP   5 vs 9             0.943       0.827       1.075 
PLANTYP   6 vs 9             0.957       0.857       1.069 
PLANTYP   7 vs 9             0.707       0.514       0.973 
PLANTYP   8 vs 9             0.938       0.825       1.067 
rxgen     1 vs 4             1.055       0.954       1.166 
rxgen     2 vs 4             1.001       0.918       1.092 
rxgen     3 vs 4             1.007       0.920       1.103 
indexyr   2011 vs 2015       0.182       0.167       0.200 
indexyr   2012 vs 2015       0.526       0.487       0.568 
indexyr   2013 vs 2015       0.690       0.639       0.746 
indexyr   2014 vs 2015       0.896       0.828       0.970 
DVT       0 vs 1             1.344       1.071       1.687 
PE        0 vs 1             1.822       1.470       2.257 
Diabetes  0 vs 1             1.023       0.971       1.077 
Vascular  0 vs 1             0.957       0.892       1.026 
ESRD      0 vs 1             1.279       1.112       1.472 
Obese     0 vs 1             1.072       1.009       1.139 
INPATIENT 0 vs 1             0.843       0.733       0.968 
cat_hosp  0 vs 1             0.887       0.791       0.994 
Statin    0 vs 1             1.016       0.973       1.061 
 
 
Association of Predicted Probabilities and Observed Responses 
 
Percent Concordant         66.5    Somers' D    0.329 
Percent Discordant         33.5    Gamma        0.329 
Percent Tied                0.0    Tau-a        0.164 
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Pairs                 531868688    c            0.665 
 
 
FINAL MODEL FOR TOTAL KNEE REPLACEMENT IN MEDICARE PATIENTS 
 
 
                      Model Information 
 
Data Set                      WORK.T4 
Response Variable             rivaroxaban          
Number of Response Levels     2 
Model                         binary logit 
Optimization Technique        Fisher's scoring 
 
 
Number of Observations Read       24480 
Number of Observations Used       24480 
 
 
           Response Profile 
 
 Ordered                         Total 
   Value     rivaroxaban     Frequency 
 
       1            1             8997 
       2            0            15483 
 
Probability modeled is rivaroxaban=1. 
 
 
                    Model Convergence Status 
 
         Convergence criterion (GCONV=1E-8) satisfied. 
 
 
       Deviance and Pearson Goodness-of-Fit Statistics 
 
Criterion          Value       DF     Value/DF     Pr > ChiSq 
 
Deviance      12811.3177     11E3       1.1727         <.0001 
Pearson       10844.9813     11E3       0.9927         0.7048 
 
Number of unique profiles: 10947 
 
 
         Model Fit Statistics 
 
                             Intercept 
              Intercept            and 
Criterion          Only     Covariates 
 
AIC           32199.321      29621.706 
SC            32207.427      29800.029 
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-2 Log L      32197.321      29577.706 
 
 
Testing Global Null Hypothesis: BETA=0 
 
 
Test                 Chi-Square       DF     Pr > ChiSq 
Likelihood Ratio      2624.9126       28         <.0001 
Score                 2413.9701       28         <.0001 
Wald                  2152.7215       28         <.0001 
 
 
         Type 3 Analysis of Effects 
 
                           Wald 
Effect         DF    Chi-Square    Pr > ChiSq 
 
agevar          1       70.6097        <.0001 
SEX             1       16.1877        <.0001 
REGION          4      673.4663        <.0001 
PLANTYP         8       38.4849        <.0001 
rxgen           3        6.4331        0.0923 
indexyr         4     1364.9215        <.0001 
DVT             1       22.6813        <.0001 
PE              1        3.0334        0.0816 
Vascular        1        5.9776        0.0145 
ESRD            1        7.7005        0.0055 
CHF             1        8.1579        0.0043 
AF              1       23.8872        <.0001 
INPATIENT       1        3.3041        0.0691 
 
 
                Analysis of Maximum Likelihood Estimates 
 
                                    Standard          Wald 
Parameter         DF    Estimate       Error    Chi-Square    Pr > ChiSq 
 
Intercept          1     -0.5562      0.5627        0.9770        0.3229 
agevar             1     -0.0204     0.00243       70.6097        <.0001 
SEX       1        1      0.1167      0.0290       16.1877        <.0001 
REGION    1        1     -0.3199      0.2602        1.5110        0.2190 
REGION    2        1      0.1678      0.2593        0.4187        0.5176 
REGION    3        1      0.7374      0.2592        8.0944        0.0044 
REGION    4        1      0.3319      0.2609        1.6186        0.2033 
PLANTYP   0        1      0.1560      0.4315        0.1307        0.7177 
PLANTYP   2        1      0.2228      0.4116        0.2932        0.5882 
PLANTYP   3        1      0.4290      0.5491        0.6104        0.4346 
PLANTYP   4        1     -0.1035      0.4144        0.0623        0.8028 
PLANTYP   5        1      0.0973      0.4163        0.0546        0.8152 
PLANTYP   6        1      0.1316      0.4115        0.1023        0.7491 
PLANTYP   7        1     -0.2648      0.5327        0.2472        0.6190 
PLANTYP   8        1      0.3103      0.4528        0.4695        0.4932 
rxgen     1        1      0.1412      0.1017        1.9298        0.1648 
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rxgen     2        1      0.0154      0.0881        0.0305        0.8613 
rxgen     3        1      0.0645      0.0907        0.5058        0.4769 
indexyr   2011     1     -2.0442      0.0701      850.4822        <.0001 
indexyr   2012     1     -0.8945      0.0559      256.4636        <.0001 
indexyr   2013     1     -0.5238      0.0558       88.0464        <.0001 
indexyr   2014     1     -0.1148      0.0580        3.9176        0.0478 
DVT       0        1      0.7033      0.1477       22.6813        <.0001 
PE        0        1      0.2330      0.1338        3.0334        0.0816 
Vascular  0        1      0.0837      0.0342        5.9776        0.0145 
ESRD      0        1      0.1788      0.0644        7.7005        0.0055 
CHF       0        1      0.2237      0.0783        8.1579        0.0043 
AF        0        1      0.3235      0.0662       23.8872        <.0001 
INPATIENT 0        1      0.1343      0.0739        3.3041        0.0691 
 
                   Odds Ratio Estimates 
 
                             Point          95% Wald 
Effect                    Estimate      Confidence Limits 
 
agevar                       0.980       0.975       0.984 
SEX       1 vs 2             1.124       1.062       1.189 
REGION    1 vs 5             0.726       0.436       1.209 
REGION    2 vs 5             1.183       0.712       1.966 
REGION    3 vs 5             2.090       1.258       3.474 
REGION    4 vs 5             1.394       0.836       2.324 
PLANTYP   0 vs 9             1.169       0.502       2.723 
PLANTYP   2 vs 9             1.250       0.558       2.800 
PLANTYP   3 vs 9             1.536       0.524       4.505 
PLANTYP   4 vs 9             0.902       0.400       2.031 
PLANTYP   5 vs 9             1.102       0.487       2.493 
PLANTYP   6 vs 9             1.141       0.509       2.555 
PLANTYP   7 vs 9             0.767       0.270       2.180 
PLANTYP   8 vs 9             1.364       0.561       3.313 
rxgen     1 vs 4             1.152       0.944       1.406 
rxgen     2 vs 4             1.016       0.854       1.207 
rxgen     3 vs 4             1.067       0.893       1.274 
indexyr   2011 vs 2015       0.129       0.113       0.149 
indexyr   2012 vs 2015       0.409       0.366       0.456 
indexyr   2013 vs 2015       0.592       0.531       0.661 
indexyr   2014 vs 2015       0.892       0.796       0.999 
DVT       0 vs 1             2.020       1.513       2.699 
PE        0 vs 1             1.262       0.971       1.641 
Vascular  0 vs 1             1.087       1.017       1.163 
ESRD      0 vs 1             1.196       1.054       1.357 
CHF       0 vs 1             1.251       1.073       1.458 
AF        0 vs 1             1.382       1.214       1.573 
INPATIENT 0 vs 1             1.144       0.990       1.322 
 
 
 
Association of Predicted Probabilities and Observed Responses 
 
Percent Concordant         68.6    Somers' D    0.371 
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Percent Discordant         31.4    Gamma        0.371 
Percent Tied                0.0    Tau-a        0.173 
Pairs                 139300551    c            0.686 
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Appendix 2: Distribution of propensity scores 
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